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Abstract          
Haematopoietic stem cell transplantation is the most effective anti-leukaemic therapy 
for AML for a large number of patients, but a significant proportion of these will relapse 
post-transplant with a poor prognosis for long-term survival.  
The bone marrow microenvironment has been implicated as a major contributor to 
chemotherapy resistance and relapse through mediating communications between 
residual cells which have been shown to preferentially support and maintain the 
leukaemic niche.  
Interactions within this malignant niche can be facilitated by exosomes, extracellular 
vesicles secreted by multiple cell types that function as delivery vehicles for mRNA, 
DNA, miRNA, enzymes and cytokines. The ability of secreted exosomes to induce 
microenvironmental changes that may differentially support normal or malignant stem 
cells in the post-transplant setting is relatively unknown.  
Characterisation of exosomes originating from MSCs revealed exosome particle 
number and protein content was significantly increased in diagnostic MSC samples 
compared to normal and post-BMT samples, along with miRNA yield which was also 
found to be significantly higher in this patient sub-set. 
Ex vivo co-culture assays using functional exosome preparations from primary AML-
MSCs revealed several phenotypic effects including exosome induced proliferation 
when co-cultured with primary AML blasts, cell adhesion and a significant protection 
against drug treatment.  
Secreted cytokine profiling by Luminex bead capture array showed that exosome 
cytokine profile change from adhesion related within the NBM and diagnostic 
samples, to immunology related targets in early-BMT and adhesion and 
survival/differentiation related in late-BMT. This change reflects a stabilization of the 
inflammatory environment towards NBM levels, along with an increase in adhesion 
related molecules suggesting a recovery post-transplant and potential early indication 
of disease relapse, GvHD or GvL. 
These results demonstrate how important extracellular vesicles are in creating a 
hostile microenvironment as promotors of residual disease, and for the first time the 
malignant potential of microenvironment derived MSC exosomes in AML.  
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1 Chapter 1: Introduction   
1.1 The bone marrow microenvironment  
 
The bone marrow microenvironment or niche is a complex network of heterogeneous 
cell populations that function either to support or are directly involved in 
haematopoiesis. The niche is home to haematopoietic stem cells (HSCs) which reside 
here either in long-term quiescence or in a transient self-renewing state until  triggered 
by cell death or damage at which point the HSCs withdraw from a quiescent state and 
actively start dividing again, this transition is regulated by several signalling pathways 
including Wnt and the MEK/ERK pathway (Baumgartner et al. 2018). HSCs give rise 
to common intermediate lymphoid or myeloid progenitor cells, which then further 
differentiate into lymphocytes, megakaryocytes/erythrocytes or 
granulocyte/macrophages which are then released into circulation for a fully 
functioning haematopoietic system (Figure.1.1). 
 
Figure 1. 1 Schematic representation of haematopoiesis (Haggstrom.M et al, 2009) 
HSCs are supported on a meshwork of stromal tissue which lines the bone marrow 
microenvironment and consists primarily of multipotent mesenchymal stem cells  
(MSCs) which are responsible for establishing this haematopoietic region (Mendez-
Ferrer et al. 2010). MSCs have the capacity to differentiate into many supportive call 
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types – adipocytes (primarily function as fat storage vehicles but also operate as a 
negative regulator of haematopoiesis), osteoblasts (synthesise bone tissue and 
regulate bone marrow angiogenesis) and chondrocytes (synthesise cartilaginous 
tissue). Two other important supportive cell types are endothelial cells (enable 
exchange of molecules between blood and bone marrow) and fibroblasts (synthesise 
structural components of bone marrow).  
The niche can be separated into two distinct parts; the endosteal and vascular niche, 
both regulate HSCs but in different ways (Perry and Li 2007). The endosteal niche is 
made up of osteoblastic lineage cells and regulatory T-cells (Treg) which are a 
specialized sub-category of T-cells that function  to prevent autoimmunity and 
promote homeostasis. Also present are sympathetic neurons which regulate HSC 
activity within the niche (Hanoun et al. 2015)  as well as MSCs. Typically hypoxic with 
low blood perfusion, quiescent HSCs prefer this environment (Semenza 2007). 
Hypoxic inducible factors (HIF) are present on the cell surface of both HSCs and 
MSCs helping to maintain a quiescent state by activating numerous downstream 
target genes such as Vegf and Cxcr4 (Andrade et al. 2015). The vascular niche is 
normoxic and consists primarily of MSCs and CAR (CXCL12-abundant reticular) cells 
which support the actively cycling HSCs which reside here (Winkler et al. 2010a). 
 
Figure 1. 2 Overview of cell types within the normal bone marrow niche (Krause and Scadden 
2015) 
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The supportive stromal cells help regulate normal haematopoiesis with the help of 
secreted soluble factors, they produce ligands and molecules that interact with their 
counterparts on the HSC surface which bring about several cellular functions. For 
example, CXCR4 is found on the surface of HSCs, is activated by the SDF-1 ligand 
which interacts with CXCL12 secreted by MSCs which brings about a chemotactic 
response. Increasing calcium levels then lead to a production of VLA-4 and LFA-1 
that adhere to HSCs and increase cell adhesion and retention (Kondo et al. 2003; 
Drury et al. 2011; Ostanin et al. 2011). 
1.2 Microenvironment and Cancer 
There are many ways the bone marrow microenvironment (BM-ME) contributes to 
cancer progression, it’s remodelling by invading cancer cells can provide a sanctuary 
site to enhance cancer cell proliferation and protect from the immune system. Within 
the BM-ME MSCs are known to function as a promotor of cancer metastasis and 
tumours recruit inflammatory cells via the expression of chemokines resulting in 
increased tumour survival, differentiation and vascularization of the tumour 
microenvironment (Joyce and Pollard 2009). The BM-ME has also been identified as 
a site of protection for cancer stem cells to reside, preserving their phenotypic 
plasticity, protecting from immunosurveillance and facilitating metastasis (Plaks et al. 
2015).   
The bone marrow is the major site of haematopoiesis and bone formation and it plays 
a key role in perpetuating many haematopoietic malignancies. Leukaemic cells 
interact with cells of the bone marrow to create a microenvironment that is favourable 
by facilitating interactions through paracrine and autocrine signalling molecules to 
increase cell proliferation, survival, adhesion and consequently chemotherapy 
resistance and the potential onset of minimal residual disease (Garrido et al. 2001; 
Huntly and Gilliland 2005).  
Alterations in the BM-ME have been reported in most human malignancies including 
breast, gastric and tumorigenesis and other haematological malignancies (Manier et 
al. 2012; Kawano et al. 2015; Purroy et al. 2015). Within tumorigenesis the BM-ME 
release of factors such as VEGFR-1 and VEGFR-2  act as a source of inflammation 
within the primary tumour, helping the formation of a pre-metastatic disease. Bone 
marrow derived VEGFR-1 positive cells alongside macrophages infiltrate hypoxic 
tumour regions and can induce CXCR-4 expression in endothelial cells of the BM-ME 
helping to promote tumour migration and angiogenesis (Reddy BY 2012). Gastric 
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cancer cells are supported within a stromal and extracellular matrix of the BM-ME 
providing adherent and secretory signals which help cancer stem cells initiate tumour 
growth  (Ishimoto et al. 2014). The BM-ME is thought to play a major role in the 
common relapse that can take place within breast cancer years after remission. It is 
thought that dormant cancer cells exist within the BM-ME forming gap junction 
intercellular communication with stromal cells creating a preferential niche in which 
cancer cells can stay long term in a quiescent state avoiding therapeutic agents which 
target proliferating cells (Chantrain CF 2008). Tumour-associated macrophages 
(TAMs) within the BM-ME are known to be involved within a paracrine loop between 
cancer cells and endothelium cells forming clusters which lead to enhancement and 
dissemination of cancer cells, increased density of these clusters has seen to 
correlate with increased development of disease within breast cancer (Joyce and 
Pollard 2009). 
 Within haematopoietic malignancies there are thought to be two possible 
mechanisms by which alterations take place; somatic mutations within the stromal 
cells  or malignant haematopoietic cells generating signals that cause altered function 
(Yao and Link 2017). There is data to support both mechanisms, but it is thought to 
be more likely that the malignant haematopoietic cells target stromal cells through the 
expression of specific factors which induce alterations in the microenvironment and 
allow the selective expansion of diseased haematopoietic progenitor cells. This gives 
the leukaemic stem cells (LSCs) a competitive advantage over normal cells and these 
changes can influence stromal response to chemotherapy and create therapeutic 
resistance (Zhang et al. 2012).  
1.3 Acute Myeloid Leukaemia 
AML is the most common adult form of leukaemia and over the last decade it’s 
incidence rates have increased by 8% in the UK to over 3000 new cases each year 
(Cancer Research UK, 2016). 
AML is characterised by an accumulation of immature and poorly differentiated cells 
in the bone marrow and peripheral blood, this leads to a disruption of normal 
haematopoiesis and bone marrow failure (Gutierrez and Kentsis 2018). Malignant 
cells can also infiltrate other tissues including the lungs, CNS and soft tissue although 
this occurs less frequently.   
AML can occur across a range of age groups although is predominantly associated 
with those over the age of 60. The mutation of a somatic stem cell subsequently 
develops into a leukaemic clone (Dash and Gilliland 2001). In addition to genetic 
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mutations, cytogenetic abnormalities can be detected in approximately 50-60% of 
newly diagnosed AML patients and are associated with certain prognostic groups. 
These usually consist of favourable (e.g. presence of inv16), intermediate (e.g. 
normal karyotype) and adverse (e.g. presence of monosomy 7) based on recognised 
risk-scores (Estey 2018). Those patients designated to adverse prognostic group 
require a more intensive therapeutic regime and are most likely to undergo allogeneic 
stem cell transplant.  
The number of coding mutations per AML genome is on average 13 per person and 
are found to reoccur in many commonly deregulated pathways, 96% of AML patients 
have at least one driver mutation in one of these genes contributing to why AML is 
such a heterogeneous disease (Bullinger et al. 2017). Cytogenetic rearrangements 
are also common and are used to diagnose AML prognosis and tracking of the 
disease at a minimal residual disease level (MRD). (Papaemmanuil et al. 2016).  
The abnormalities underlying AML are heterogeneous and new mutations commonly 
arise in response to treatment and at relapse, making it a very complex disease which 
is difficult to treat.  
1.4 Treatment of AML 
Treatment for AML patients is mainly with chemotherapeutic drugs that inhibit cell 
proliferation. Treatment usually consists of two phases, intensive induction therapy 
which aims to eliminate the majority of leukaemic cells and consolidation therapy 
which aims to maintain long term remission (Rowe 2009).  
Older AML patients defined as over 65 years of age are much less likely to tolerate 
standard intensive cytotoxic treatment and over the last 50 years have shown limited 
improvement in treatment outcome with low dose regimes compared to the younger 
age patient group (Burnett 2012).  
Due to the heterogeneous nature of AML along with other important prognostic factors 
such as cytogenetics and age, patient stratification is complex and essential in order 
to tailor treatment to achieve adequate therapeutic effect. For patients of adverse 
prognostic group especially there is an unmet clinical need for more effective 
therapies, especially since treatment has not changed significantly in the last 30 
years. Bone marrow transplant may be the only option for poor prognosis patients, 
but  for many elderly patients this is not  viable  (Duarte et al. 2018). 
Diagnostic molecular information is used to track disease progression this is 
particularly important when monitoring MRD (minimal residual disease) and when 
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deciding on therapies which target specific molecular mutations for example isocitrate 
dehydrogenase (IDH) inhibitors used to treat IDH mutation (Koreth et al. 2009; Stone 
et al. 2017). 
Standard treatment for AML consists of two phases, a remission induction phase and 
a consolidation therapy phase. The induction phase consists of a combination of 
cytarabine (Ara-C) treatment alongside an anthracycline, usually daunorubicin. 
Cytarabine is a pyrimidine analogue which functions by disrupting DNA synthesis 
resulting in a reduction of cell proliferation. Anthracyclines are antibiotics which 
function to reduce luekaemic burden (Dohner et al. 2010). 
Following induction phase, if complete remission (CR) is reached patients will go on 
to receive post-remission therapy which consists of either consolidation 
chemotherapy or haematopoietic stem cell transplantation, or a combination of both. 
Treatment is based on the disease and patient characteristics and availability of a 
donor for transplant (Thol et al. 2015).  
Advances have been made in the molecular characterization of AML subtypes 
allowing patients to receive more effective treatment, but the greatest challenge 
remains the effective targeting of relapsed disease. The standard therapy as outlined 
above incur significant toxicities and risk of disease recurrence is still high, new 
treatments which are lower in toxicity are particularly required for the elderly and those 
that are transplant ineligible (Altman and Platanias 2013). 
Due to the challenges in treatment of AML studies have concentrated on developing 
therapies which identify specific targets which could potentially be used in 
combination with chemotherapy, a successful example of this is the targeting of FLT3, 
clinical trials with targeted FLT3 inhibitors report around a 50% response rate in 
patients harbouring a FLT3-ITD mutation (Wander et al. 2014). Other possible targets 
include; CREB a transcription factor which regulates gene expression and functions 
as a protooncogene in haematopoiesis, Triad1 is an E3 ubiquitin ligase and a target 
of HoxA10 know to have pro-leukaemogenic effects, Bcl-2 family critical regulators of 
the apoptotic pathway with a high association with AML, JAK/STAT pathway is 
commonly activated in myeloproliferative disorders which commonly progress to AML 
(Andreeff et al. 1999; Kralovics et al. 2005; Marteijn et al. 2005; Shankar et al. 2005). 
1.5 Bone marrow transplantation in AML  
Allogeneic stem cell transplantation is still the most effective anti-leukaemic therapy 
for adverse prognostic AML and over a third of haematopoietic stem cell transplants 
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(HSCTs) are performed as therapy for AML worldwide (Niederwieser et al. 2016). A 
significant proportion of patients will relapse post-transplant and the probability of long 
term survival following early relapse is less than 20% (Tsirigotis et al. 2016).  
Assessment of patients for HSCT is based on several factors which include disease 
risk, patient comorbidity and the willingness of the patient to take part in the 
procedure. A prognostic scoring system is commonly employed to help aid decision 
making e.g. Haematopoietic Cell Transplant Co-morbidity Index (Christopeit et al. 
2013). 
Patients over 60 and adverse risk disease at high risk of relapse (70-90%) can be 
offered HSCT if generally fit with the introduction reduced intensity conditioning 
regimes (RIC). Standard approach when considering a HSCT for AML is to find a 
human leukocyte antigen (HLA) matched sibling donor, if this is not possible then an 
alternative donor may be considered.  
AML transplant patients are stratified depending on their molecular subtype, this is 
important as it allows risk estimation and post-remission treatment to be identified 
appropriately (Koreth et al. 2009). 
Sequential chemotherapy as a conditional regimen is used preceding HSCT and 
consists of a combination of anti-leukaemic and immunosuppressive therapies. In 
order to prevent graft-versus-host-disease (GvHD) immunosuppression therapy is 
essential and comprises of immunosuppressant drug treatment. There are two forms 
of GvHD, the most common is acute GvHD which can occur as early as a week 
following HSCT and takes place when alloreactivity between donor derived T-cells 
and the recipient’s antigens. Chronic GvHD can take place 3 months+ following HSCT 
and is thought to involve alloactivation of donor CD4 and CD8 T-cells, although this 
mechanism is not yet fully understood (Kassim and Savani 2017).  
Post-transplant (MRD) and chimerism status of the patient are monitored to assess 
graft success, although neither provide definitive guidance on whether a patient will 
relapse. Treatment with donor lymphocyte infusion (DLI) administered as a boost of 
immune cells from the donor can help to control relapse and potential leukaemic blast 
resurgence. Weaning off immunosuppressive therapy takes place following HSCT 
and monitoring of patient for signs of GvHD (Tsirigotis et al. 2016).  
HSCs used for transplant are collected from either BM or more commonly peripheral 
blood (using GCSF mobilization treatment), and intravenously transplanted into the 
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the recipient where the cells  then ‘home’ into the niche through the sequential 
activation of a variety of adhesion molecules (Podesta 2001).  
Within the BM-niche, CXCL12 along with intercellular and vascular cellular adhesion 
molecules 1 (ICAM/VCAM) activate CXCR4+ progenitors which leads to their 
adhesion to endothelial cells. Cells which express insufficient CXCR4 detach and 
return to the bloodstream. CXCL12 and macrophage inflammatory protein-1 (MIP-1) 
then activate the binding of CD34+ cells into the extracellular fibronectin matrix of the 
BM niche via VLA-5 and VLA-4 integrin receptors (Kollet et al. 2001). The final stage 
of homing involves the migration of stem cells into the BM- niche where they interact 
with supporting cells, adhesion molecules, CXCL12 and growth factors. MSCs have 
been identified as an important contributory factor for a successful HSC engraftment. 
Several clinical trials have used MSCs to reduce aplasia post chemotherapy, prevent 
graft versus host disease (GvHD) and prevent overall transplant failure (De Luca et 
al. 2017), although the mechanism of action for this support is largely unknown.  
The homing of the transplanted cells results in a depletion of progenitors and so only 
a small percentage of the recipient’s stem cell pool is made up of these. The 
transplanted stem cells divide slowly but should generate enough progenitors to 
repopulate the host haematopoietic system to normal levels within 2 years of stem 
cell transplant (Lanzkron et al. 1999; Mahmud et al. 2001). 
AML patients that relapse after transplantation have a poor prognosis (Figure 1.3), 
although current studies have shown that if treatment is started at molecular relapse 
rather than clinical relapse the results are more positive, however this requires regular 
monitoring of a suitable MRD marker which is not always present for all patients 
(Bejanyan et al. 2015). 
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Figure 1. 3 Chart showing overall survival for patients with AML after first relapse based on 
previous transplantation (Forman and Rowe 2013). 
Treatment for relapse of AML after transplant has one of two aims, to prevent 
leukaemic activity usually in the form of chemotherapy or enhance the immunological 
graft-vs-leukaemia (GvL) effect usually in the form of donor lymphocyte infusions (Orti 
et al. 2017; Stone et al. 2017).  
Another possible treatment following relapse is a second stem cell transplant, but this 
is normally only suitable for younger patients due to the severe effects on the body. 
A recent study on AML patients showed that the 2-year OS rate after a second stem 
cell transplant was only 25% (Christopeit et al. 2013).  
 
1.6 The bone marrow microenvironment as a driver of AML    
During leukaemogenesis AML cells invade the BM-ME disrupting normal 
haematopoiesis and impeding the maturation of HSCs residing there (Morrison and 
Scadden 2014) (Figure 1.4) 
 
Figure 1. 4 Overview of cellular interactions that take place within the bone marrow 
microenvironment (Figure adapted from (Behrmann et al. 2018). 
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Once initiated, the LSCs manipulate the niche to their advantage allowing LSC 
expansion and chemoresistance before eventually remodelling the bone marrow 
microenvironment to produce a ‘leukaemic niche’ increasing the hypoxic environment 
which favours LSC survival and proliferation over normal haematopoiesis (Lane et al. 
2009) (Figure 1.5). LSCs behaviour within the BM-niche is also modulated by 
interactions and signals with the various cell types that reside there such as 
endothelial, osteoblast and mesenchymal stem cells  (Tabe and Konopleva 2015).  
 
  
  
Figure 1. 5 Summary of differences between normal HSC endosteal niche compared to 
malignant LSC favourable endosteal niche. (Figure adapted from (Zhou H-S 2016) 
Many studies suggest that not only does the BM-niche contribute to the acceleration 
of malignancy but that cellular and molecular changes can directly induce leukaemia. 
Two landmark studies by Walkley et al showed that genetic changes to the 
heamatopoietic and stromal cells of the BM-niche in the form of retinoblastoma gene 
deletion gave rise to myeloid disorders and showed that these genetic alterations 
within the niche were essential for disease initiation (Walkley et al. 2007). Studies 
have shown that dysregulation  within osteolineage cells of the haematopoietic stem 
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cell niche can lead to the induction of myelodysplasia and secondary leukaemia 
(Raaijmakers et al. 2010). Extensive work carried out on murine models suggests that 
changes within the BM-ME can directly cause haematological abnormalities. 
Neoplastic changes causing disruption within osteolineage cell specific Dicer1 led to 
the development of AML, and those mice with osteoblast specific constitutively active 
β-catenin led to disruption  of the Notch signalling pathway leading to AML (Kode et 
al. 2014).  
These studies demonstrate a direct causal role for many of the cellular components 
that make up the BM-niche in the development of a number of myeloid diseases. The 
most commonly deregulated mechanisms implicated are Notch and Wnt signalling 
pathways and an increased production of pro-inflammatory cytokines (Schepers et 
al. 2015).  
MSC’s have been recognised as playing a major role in the leukaemic malignancy 
process, they increase the expression of several key niche factors that selectively 
support growth of LSC over HSC. VCAM-1 typically expressed on MSCs associates 
with CXCL12 which expresses CXCR4 on the cell surface of the leukaemic blast 
leading to LSC resistance and survival advantages (Jacamo et al. 2014). AML cells 
have been shown to block MSC differentiation into mature osteoblasts and instead 
induce the production of an osteogenic niche which acts as a sanctuary for LSCs and 
becomes inhospitable for normal HSCs (Battula et al. 2017). It has also been reported 
that MSC quiescence within the niche is disrupted by AML cells which reduce the 
density of the nerve network that is critical in order to maintain MSC in a state of 
quiescence and subsequent osteoblast differentiation and HSC survival (Yamazaki 
et al. 2011).  
The BM-ME hosts a number of immunological cell types some of which are affected 
by the presence of a leukaemic niche. A reduction in numbers of T-cells and NK-cells 
is seen alongside an increase in Treg cells, thought to be instigated through the 
activation of immune markers, for example PD-1 whose expression levels are seen 
to correlate with AML development (Zhang et al. 2009). Macrophages associated with 
AML are also seen in higher numbers within the leaukaemic niche helping to support 
their advancement (Winkler et al. 2010b). 
Endothelial cells have been shown to aid the adherence and retention of AML cells 
within the BM-niche via the expression of E-selectin on their cell surface which AML 
cells recognise and readily adhere to. Endothelial cells also secrete the ligand VCAM-
1 which interacts with the receptor VLA-4 on the AML blast cell providing another 
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potential site of anchorage (Becker 2012). Endothelial cells express VEGF 
recognised by VEGFR on AML cells which is a pro-angiogenic factor and an important 
contributing factor to increased leukaemogenesis (Fiedler et al. 1997). 
VEGF expression by AML blasts induces neo-angiogenesis, this is known to increase 
within the BM-niche at diagnosis, recovering to normal levels at disease remission. 
Microvessel density (MVD) is a measure of angiogenesis and is used as a prognostic 
factor for patients, a higher MVD is associated with poor prognosis and increased risk 
of relapse (Schepers et al. 2015). 
Within the BM-niche leukaemic cells secrete VEGF and other angiogenic factors upon 
integration into blood vessel walls, the release of growth factor angiopoietin (Ang) in 
combination with VEGF causes destabilization, degeneration and sprouting of blood 
vessels and which leads to increased angiogenesis and increased proliferation of 
malignant cells.  
The role of fibroblasts in AML development is unclear but research has shown that 
an increase within the BM-ME has a protective effect on AML blasts (Zhai et al. 2016). 
A possible mechanism is via the release of the ligand MMP2 which is recognised by 
the receptor EMMPRIN on the AML blast and has been shown to lead to a reduction 
in apoptosis of AML cells (Gao et al. 2015). Fibroblasts make up a large proportion of 
the cells within the BM-niche but their function within the leukaemic niche is still not 
fully understood. Fibroblasts can produce extracellular matrix fibres and secrete 
cytokines and chemokines, and studies have shown that fibroblasts are involved in 
mechanisms of  chemoresistance in solid tumours and AML, but it is not yet clear how 
this is achieved (Shirai et al. 2009; Zhai et al. 2016).  
1.7 Bone marrow niche-mediated survival of leukaemia stem cells  
Residual LSCs in the BM-niche are thought to play a large role in disease relapse 
and due to the poor prognostic outlook for relapsed AML patients, the interactions 
between LSCs and the BM-niche are thought to be an important therapeutic focus 
(Chiarini et al. 2016). 
It is thought that the BM-niche mediates resistance to chemotherapy via several  
possible mechanisms, soluble factor-mediated drug resistance (SM-DR) consisting 
of the secretion of small molecules by osteoblasts, endothelial and stromal cells or 
cell adhesion-mediated drug resistance (CAM-DR) which is direct contact mediated 
by adhesion factors.  
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The direct interaction of AML blasts with the surrounding stromal supportive cells has 
been shown to increase their survival and offer therapeutic protection. AML induced 
changes of cytokine/chemokine secretory profile of the stroma has been shown to 
mediate the expression of receptors functioning as homing and protective devices for 
AML blasts (Sansone and Bromberg 2012; Civini et al. 2013). 
Chemosensitivity within the BM-niche is mediated by cross talk between CXCL12 and 
CXCR4 (Ponomaryov et al. 2000). CXCL12 is a powerful chemoattractant for both 
HSCs and LSCs and CXCR4 activation has been shown to mediate the migration of 
AML cells beneath BM stromal cells. Malignant cells use CXCR4 to aid access to the 
protective niche which normally houses HSCs, and gives protection to drug treatment 
and encourages cell expansion (Burger et al. 2003). Studies have shown that 
upregulation of surface CXCR4 on AML cells creates a possible mechanism for drug 
resistance, the use of a CXCR4 small molecule inhibitor called AMD3465 successfully 
increased the sensitivity of AML cells to chemotherapy in vitro and in vivo. It is thought 
the inhibition of the CXCR4 pathway disturbs cell-matrix communication and 
encourages malignant cells to move from the quiescent sanctuary of the endosteal 
niche, and increase the chemosensitivity of the leukaemic cells (Andreeff et al. 2006; 
Zeng et al. 2009). 
In vivo dynamic imaging has revealed that LSCs home and create vascular niches in 
cranial BM vasculature (Sipkins et al. 2005). Cells of the BM-niche secrete a variety 
of soluble factors some of which help regulate and retain LSC cells. CXCL12/SDF-1 
is secreted by MSCs and binds to CXCR4 on leukocytes helping to regulate their 
transportation during normal hematopoiesis. CXCR4 expression on LSCs has been 
shown to bind to SDF-1 expressed by vessel endothelium and instigating LSC homing 
to the vascular niche (Sipkins et al. 2005). During chemotherapy it was observed that 
LSCs increase their expression of CXCR4 leading to an increase in survival and 
conferring resistance to therapy. Further confirmation of this mechanism was seen 
when CXCR4 was inhibited in AML cells and resulted in an increase in therapeutically 
induced apoptosis (Peled and Tavor 2013). Studies on CML have shown that the 
controlled release of soluble factors by BCR-ABL+ CML cells which included the 
decrease in CXCL12 and increase in GCSF, led to the movement of HSC cells out of 
the BM-niche and into the periphery, leaving it free for LSC monopoly (Zhang et al. 
2012). 
B-lymphoma cells have also been shown to produce soluble factors in the form of 
FGF4 which signals through FGFR1 on endothelial cells within the BM-niche, this 
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leads to an increased expression of Notch ligand Jagged1 which goes on to activate 
the Notch2 expressed on B-lymphoma cells leading to an increase in their 
proliferation (Cao et al. 2014).  
Osteoblasts have been shown to play an important role in resistance to therapy in 
AML through both SM-DR and CAM-DR. Studies show that osteoblasts protect both 
CXCL12-expressing cell lines and primary AML cells from CXCL12-induced death via 
a SM-DR mechanism (Kremer et al. 2014). HSCs and LSCs are both known to tightly 
adhere to osteoblasts on the BM surface or stroma via a combination of integrins, 
cadherins and fibronectin and osteopontin, these interactions encourage cell 
mobilization and homing to the BM-niche leading to increased drug resistance 
(Kremer et al. 2014).  
The differentiation of mature osteoblasts is blocked by LSCs inhibiting the 
sympathetic nervous system and inducing the secretion of CCL3. This leads to 
lowering osteocalcin levels and the construction of a pro-osteoblastic niche which 
contains high numbers of osteoprogenitor cells needed for LSC expansion alongside 
a reduction in normal haematopoiesis (Yamazaki et al. 2011; Frisch et al. 2012).  
Osteopontin (Opn) is secreted by the osteoblasts within the BM-niche and is known 
to play a key role in maintaining cell quiescence, invasion and MRD. Studies have 
shown a correlation between increased expression of Opn and poor prognosis in AML 
(Liersch et al. 2012). It is thought that leukaemic cells expressing and secreting Opn 
are recruited to the BM-niche where they establish a Opn-rich region regulated by 
host-malignant cell exchanges via various integrins that interact with receptors 
expressed on Opn (Boyerinas et al. 2013). This protective malignant niche results in 
the expansion of the quiescent LSC population and resistance to chemotherapy. 
Interactions between angiopoietin-1 (Ang-1) in osteoblasts and Tie-2 on HSCs give 
rise to many effects in cell adhesion, survival and quiescence (Reikvam et al. 2010). 
Tie-2 is a receptor tyrosine kinase expressed by both endothelial cells and AML cells, 
when it binds to Ang-1 it becomes phosphorylated and this activates the PI3-kinase 
– AKT signalling pathway (Bachegowda et al. 2016). Studies have shown the Ang-
1/Tie-2 interaction brings about changes to the cell cycle, promoting cell cycle arrest 
in leukaemic cells, stopping cell division and maintaining self-renewal (Gomei et al. 
2010). 
AKT is known to suppress apoptosis, regulate proliferation and contribute to cancer 
progression and metastasis, it’s activation results in HSC proliferation and it is thought 
could be involved in leukaemic transformation (Kharas et al. 2010). AKT can 
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phosphorylate FOXO transcription factors which aid the shuttle of FOXO proteins 
from cell nucleus to cytoplasm, this mechanism has shown to protect HSCs from 
noxious stresses, lower cell metabolism and help maintain HSCs in a quiescent state 
(Suda et al. 2005). Studies have shown that activation of the PI3K/AKT pathway in 
AML patients led to a favourable outcome, it has been hypothesized that this 
activation could promote entry of LSCs into the s-phase of the cell cycle making them 
more vulnerable to chemotherapy (Tamburini et al. 2007). 
Endothelial cells are a major component of the BM-niche and due to their key 
positions within the vascular niche, LSCs migrate to these areas in order to develop 
vasculature (Cogle et al. 2014).  
Adhesion molecules play an important role in successful engraftment of LSCs into 
the BM-niche. VLA-4 (very late antigen 4) is a cell surface ligand for VCAM-1(vascular 
cell adhesion molecule 1) found on MSCs and highly expressed on AML cells, this 
activates various pathways through NF-κB and helps mobilize and secure leukaemic 
cells into the niche and is also implicated in MRD (Papayannopoulou et al. 1995). The 
VLA-4/VCAM interaction within the niche encourages AML cells to adhere to 
surrounding endothelial cells which become activated by the release of VEGF-A 
which caused endothelial cells to form a chemoprotective barrier to AML cells this 
was further confirmed by studies which showed upon inhibition of VEGFR the 
chemosensitivity of AML cells increased (Poulos et al. 2014). AML patients which are 
VLA-4 negative are given a favorable outcome (Matsunaga et al. 2003; Jacamo et al. 
2014). 
The role of hypoxia within haematological malignancies is controversial as there are 
many contradictory studies claiming hypoxia is both a positive and negative regulator 
of haematological disease progression (Drolle et al. 2015; Velasco-Hernandez et al. 
2015). It is clear that activation of the HIF-1α pathway within the BM-niche results in 
increased angiogenesis and higher levels of cytokine secretion which results in an 
increase of the resistance of malignant cells to chemotherapy. Hypoxic 
microenvironment also plays a role in regulating the expression of CXCR4 leading to 
drug resistance  (Fiegl et al. 2009). In summary, hypoxia plays an important indirect 
role in regulating drug resistance and disease progression. 
LSCs have been shown to prefer to reside within the endosteal niche, this is typically 
a more hypoxic environment and LSCs are seen to localize and interact with 
surrounding cells including MSCs (Ninomiya et al. 2007). Just like the hypoxic 
endosteal niche seen in the normal BM-niche which houses HSCs, AML can bring 
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about genetic changes in MSCs enabling them to differentiate into osteolineage 
progenitors and start the modelling of a leukaemic niche (Raaijmakers et al. 2010). 
The hypoxic environment within the LSC niche becomes more extended than that 
seen in the normal niche which studies have shown is essential for LSC growth and 
survival (Benito et al. 2011). 
LSCs play an important role in creating drug resistance in AML, they interact directly 
with the BM-niche and remodel it to create a protective niche that allows them to 
maintain a quiescent population and increases their self-renewal along with 
multilineage differentiation (Ishikawa et al. 2007). Relapse after chemotherapy is 
characterized by a more genetically heterogeneous and complicated LSC population 
(Ho et al. 2016).  
Work carried out in ALL showed tunneling nanotubules (TNT) within the leukaemic 
niche which were used by LSCs to make contact with MSCs and induce secretion of 
various soluble factors which increased LSC survival and improved resistance to 
therapy. TNTs have also been observed in AML, in order to transport mitochondria 
between BM stromal cells, and AML blast cells within the BM-niche leading to 
improved AML cell survival. Stimulation of the transfer via the TNTs is driven by the 
generation of superoxide through NOX2 which stimulates the MSCs to carry out this 
mitochondrial transfer (Marlein et al. 2017). In vitro work has shown that the 
cholesterol lowering drug lovastin inhibited the growth of LSCs when co-cultured with 
MSCs but showed no affect when cultured alone, suggesting a link between metabolic 
activity and the  support of AML survival within the BM-ME (Hartwell et al. 2013).   
A recent study suggested that leukaemic cells can influence stromal response within 
the BM-niche in response to chemotherapy. The study involved the use of mice 
engrafted with human ALL cells and showed that following chemotherapy exposure 
a novel, but transient niche formed within the BM. This niche consisted of nestin1 
leptin receptor MSCs surrounding ALL cells. The niche cells generated signals that 
confer resistance to drug treatment in the residing ALL cells, and some of these 
signals stimulated the release of pro-growth factors (Duan et al. 2014).  
The adhesion molecule E-selectin is expressed on endothelial cells and binds to 
CD44 which is commonly expressed on LSCs creating an adhesion partnership within 
the BM-niche. Studies have shown that inhibition of CD44 and E-selectin leads to 
increased chemosensitivity of AML and a decrease in LSCs, signifying the protective 
nature of the BM-niche (Jin et al. 2006; IG et al. 2014). 
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There are several clinical trials aiming to address the barriers to chemotherapy 
created by LSCs within the BM-niche and reducing relapse and MRD in AML. 
Examples include; targeting CXCL12/CXCR4 axis using CXCR4 inhibitors to block 
the interaction of leukaemic cells with niche cells and reduce chemotherapy 
resistance, CXCR4/E-selectin inhibitor, more efficient dual function target, VLA-4 
inhibitor to restore chemotherapy sensitivity and Hypoxia-activated prodrug (HAP) to 
address the hypoxic malignant BM-niche (Zeng et al. 2009; Layani-Bazar et al. 2014; 
Badar et al. 2016; Fogler et al. 2016) 
1.8 Exosome biogenesis and mode of action  
Extracellular vesicles are lipid-bilayer-delimited particles that are naturally released 
from cells and cannot replicate, they range in size from 20 – 1000nm. Diverse 
categorisation of extracellular vesicles has been proposed over the years, but this is 
a fast-changing field and consensus regarding nomenclature is not definitive. The 
following sub-types of extracellular vesicles are currently agreed (Ciardiello et al. 
2016) : 
- Ectosomes/microvesicles/microparticles (plasma membrane origin) 
- Exosomes (endosomal origin) 
- Apoptotic bodies 
- Large oncosomes and other large extracellular vesicles 
- Enveloped viruses 
- Exomeres 
For the purpose of this thesis I have chosen to refer to exosome as the extracellular 
vesicle sub-type that I believe to be relevant to my work. 
Exosomes are the smallest within the family of extracellular vesicles and were first 
identified in 1983, and within the past ten years have become the focus of increasing 
scientific interest, consequently the field is constantly evolving as there is still much 
unknown (Pan et al. 1985). When exosomes were first identified they were initially 
believed to function primarily as waste disposal units, removing unnecessary proteins 
and other molecules from  cells. It wasn’t until the mid-1990’s that exosomes were 
recognised as having an immunological function and since then numerous studies 
have implicated exosomes as having direct involvement in various biological 
processes. These processes include; inflammation, immune response and 
proliferation, stem cell maintenance and repair, tissue regeneration following injury 
and wound healing  and within the development and progression of various diseases 
including most recently, cancer (Borges et al. 2013; M et al. 2017).  
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Exosomes are defined as 30-100nm in diameter and of endosomal origin, these two 
factors are the major defining features that set exosomes apart from other 
microvesicles (Kowal et al. 2014). The biogenesis of exosomes starts with the fusion 
of early-late endosomes forming multivesicular bodies (MVBs), the MVB membrane 
invaginates and forms intraluminal vesicles, a process which is partly driven by the 
endosomal sorting complex required for transport (ESCRT) (Hanson and Cashikar 
2012). ESCRT consists of four protein complexes; Hrs, TSG101, STAM1 and VPS4B, 
all have been shown to support the inward budding process and the assemblage of 
exosome cargo (Henne et al. 2013). An ESCRT independent biogenesis has been 
observed but it is uncommon and thought to be driven instead by the presence of 
certain lipids (Babst 2011) (Figure 1.6) 
 
Figure 1. 6 Overview of the formation and biogenesis of exosomes and microvesicles within 
a cell (adapted from (Abreu et al. 2016). 
 
When an exosome is formed the cell membrane becomes enriched with tetraspanins, 
these are proteins which are involved in many biological processes including cell 
adhesion, motility, invasion, membrane fusion, signalling and protein trafficking 
(Thery et al. 2009). The tetraspanins CD9, CD63 and CD81 are especially enriched 
on the membrane of exosomes and their presence is commonly used for 
identification. These proteins can also function as a selector of exosome cargo 
(proteins and miRNA), an aid to the binding and uptake of exosomes by target cells 
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and by presenting themselves to antigens and stimulating an immune response 
(Andreu and Yanez-Mo 2014). 
It is thought that this selection process takes place using ubiquitination of proteins on 
the cell surface which act as a marker. Lipid rafts commonly observed on the 
membrane of exosomes can also function as cell signaling and sorting molecules 
(Stuffers et al. 2009). 
The sorting of cargo into exosomes is suggested but not extensively proven so far to 
be selective, this is based on evidence that cargo carried by exosomes can differ from 
that of the parental cell. Information is delivered to precisely targeted recipients, which 
implies that the information carried must be programmed by the parental cell to be 
directed and specific (Ciardiello et al. 2016). 
Once cargo has been sorted into exosomes the MVBs then either transfer to 
lysosomes where their content is degraded, or they are directed to the plasma 
membrane via an actin and microtubule cytoskeleton to dock and fuse (Hoshino et al. 
2013). SNARE complex of proteins which consists of four SNARE protein helices at 
the plasma membrane are thought to facilitate the fusion of the MVBs with their target 
membrane and subsequent exosome release (Bonifacino and Glick 2004). Calcium 
levels within the cell also have an impact on the release of exosomes with a higher 
number of exosomes released in parallel with a rise in concentration of intracellular 
calcium, commonly seen within the bone marrow niche (Savina et al. 2003) 
Rab GTPases 27A and 27B also play an important role within the late stages of 
exosome production, they help regulate vesicle budding, the transport of vesicles 
within the actin and tubulin cytoskeleton, and mediate fusion between the plasma 
membrane. It has been hypothesised that they are also involved in exosome 
secretion, but current studies show contradictory results therefore more work is 
needed to confirm this (Ostrowski et al. 2010). The transcription factor p53 a tumour 
suppressor gene commonly mutated within cancer patients, has also been implicated 
in exosome release. Studies have shown that activation of p53 gives rise to greater 
numbers of exosome release, and p53 knockout mice showed a severe reduction in 
exosome production.  It is hypothesised that these exosomes contribute to the spread 
of malignancy by transfer of the protein TSAP6 which in turn leads to  increased 
abnormal intracellular communication and induction of  gene expression changes of 
non-diseased cells (Yu et al. 2006; Lespagnol et al. 2008).  
Exosome content differs from cell to cell but always contains a combination of 
proteins, lipids and RNA. The main component of exosomes are lipids, they are 
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enriched in several different types e.g. cholesterol, as well as certain bioactive lipids 
e.g. prostaglandins and enzymes involved in lipid metabolism (Record et al. 2014). 
Protein content of exosomes depends on the cell of origin, they will share some 
membrane components and markers of the parental cell, but some physiological 
conditions and cell stimulation such as oxidative and thermal stress or 
chemotherapeutic agents can have an impact. An exosome which is derived from an 
antigen-presenting cell will be enriched in Ag-presenting molecules such as MHC-I 
and II complexes. Exosomes also contain key proteins involved in many important 
cell signalling pathways; NOTCH and Wnt-β-catenin pathways and interleukins, all 
important in regulating proliferation, differentiation and regulating immune response 
within the cell (Thery et al. 2009). Exosomes carry RNA in the form of mRNA, miRNA 
and lncRNAs which have all been shown to be functional in recipient cells, allowing 
their genetic modification by changing their translational profile (Skog et al. 2008). 
miRNA is generally seen at high concentrations within tumour cells and can differ 
significantly from parental cells. Work carried out using microarray analysis compared 
miRNA content of exosomes and their parental cell, results showed major differences. 
Certain mIRs were up to one thousand times more concentrated in exosome content, 
this indicates that there must be some miRNA preferential sorting mechanism, the 
process of which is not yet very well understood (Rabinowits et al. 2009; Hornick et 
al. 2015). The presence of certain sequence motifs and post transcriptional changes 
could indicate a possible sorting mechanism (Abels and Breakefield 2016) Figure 1.7. 
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Figure 1. 7 The composition of an exosome showing both membrane bound and cytosolic 
molecular content. (Figure adapted from (M et al. 2017). 
Uptake of exosomes is not fully established but endocytosis is the most commonly 
reported method, predominantly under the mediation of clathrin (Tian et al. 2014a). 
Phagocytosis (Feng et al. 2010), direct fusion with the plasma membrane (Parolini et 
al. 2009) or binding through exosomal adhesion molecules (Pan et al. 1985) are all 
possible alternatives but it’s not clear whether this uptake is cell specific (Feng et al. 
2010). 
 
1.9 Exosomes and Cancer  
Exosomes play an important role in several pathological processes within the human 
body and have been implicated in the progression of many diseases such as HIV 
(Teow et al. 2016), Parkinson’s disease, Alzheimer’s disease (Vella et al. 2016) and 
numerous inflammatory conditions (Lee et al. 2016). A significant interest is shown in 
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the extensive role exosomes play within multiple stages of cancer progression 
(Meehan and Vella 2016). 
The way exosomes interact within cancer progression can be broken down into three 
key areas of association – the modulation of immune response, cross-talk within the 
malignant microenvironment and metastasis development (Ruivo et al. 2017). 
Exosomes aid cancer immunosurveillance by presenting antigens to CD4+ and CD8+ 
T-cells via the MHC-I and II complexes on their cell surface. They also play a role 
mediating proliferation of HSCs and subsequent activation of NK cells which can go 
on to regulate an antigen specific immune response, leading to potential eradication 
of neoplastic cells (Yao et al. 2013). Exosomes also form an important part of the 
mechanisms involved in creating an immunosuppressive environment utilised by 
cancer cells to evade immunosurveillance via delivery of factors such as FAS ligands, 
that are capable of inducing apoptosis in the surrounding immune cells (Andreola et 
al. 2002).  
Tumour-derived exosomes (TEX) can transfer information to recipient cells at local 
and distant locations within the body. Tumour cells which normally exist within hypoxic 
conditions such as the bone marrow, secrete large numbers of TEX. These 
communicate with other tumour cells or using either receptor/ligand signaling, plasma 
membrane fusion, phagocytosis or endocytosis, reprogramme recipient cells (King et 
al. 2012; Mulcahy et al. 2014). This reprogramming is thought to take place via the 
exchange of genetic material and signaling changes, which adapt the recipient cell 
RNA and create adjustments to the proteome (Mulcahy et al. 2014).  
TEX are used to reprogram immune cells to escape host immunosurveillance and 
carry several immunoinhibitory molecules on their cell surface such as CD95 (FasL) 
and PD-L1 (Kim et al. 2005), TAAs (tumour associated antigens) expressed by the 
parental cell (Andre et al. 2002) and oncogenes or oncogenic proteins (Rak and Guha 
2012).  
TEX deliver signals to T-cells via receptor/ligand mediated signaling which causes an 
increase in intracellular calcium, which activates downstream signaling that changes 
the recipient cell transcriptome and it’s function. Immune cells interaction with TEX 
varies, lymphocytes and monocytes very quickly internalize TEX, the method of 
transfer is thought to be dependent on the cargo being delivered (Muller et al. 2017). 
The result of reprogramming by TEX is an increase in growth of the parental tumour 
cells which is supported by a combination of cytokine and soluble factor release within 
the tumour microenvironment and periphery (Whiteside 2017). 
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TEX involvement in producing dysfunctional immune cells can also take place via 
negative signaling, and there is evidence to show that TEX signaling on recipient T-
cells regulated the signal in a negative manner by inducing down-regulation of CD3-
associated zeta chain (Taylor et al. 2003). TEX have also been shown to modulate 
transcription factors of recipient T-cells by activating the phosphorylation of STAT-5 
in activated CD4+ T-cells, and inhibiting STAT-5 phosphorylation in activated CD8+ 
T-cells. As a result of this negative signaling, immune cells are restricted from 
eliminating the invading tumour cells (Whiteside 2013). 
Dendritic cells have also been associated with anti-tumour immune responses, in vivo 
studies have shown that DC-derived exosomes cause activation of T-cells due to 
cross-presentation of tumour antigens. This shows that exosomes derived from 
different pathogenic parental cells can collectively bring about an immune response 
(Zitvogel et al. 1998) 
Tumour-associated macrophages have shown to benefit from exosomes within key 
pathways associated with tumour development (Noy and Pollard 2014). Studies in 
breast cancer show that cancer derived exosomes cause activation of NF-κB in 
macrophages. This is known to bring about inflammatory response and release of 
various growth factors and cytokines, creating a permissive tumor microenviroment 
(Chow et al. 2014). 
Cancer exosomes play an important role creating the tumour microenviroment by 
improving communication between the large network of supportive and malignant 
cells, helping to modulate and reprogram the surrounding cells to support and 
promote cancer cell proliferation. Tumour growth depends on access to nutrients and 
so vasculature within the tumour-micoenvronment is essential, exosomes have been 
shown to stimulate endothelial cells to secrete certain soluble factors which stimulate 
angiogenesis (Kucharzewska et al. 2013). 
Exosomes play an important role in metastasis that depends on cell transport and 
invasive properties in order to survive and grow. Cancer cells use exosomes to induce 
invapodia formation, structures which help degrade the extracellular cell membrane 
allowing cancer cells to cross the endothelial barrier of recipient cells (Hoshino et al. 
2013). Following invasion, cancer cells commonly go on to colonize a secondary site 
and direct this process through the expression of integrins (Hoshino et al. 2015).  
Exosome involvement in haematological malignancies has not been as widely 
investigated as those in solid cancer, but they are believed to play a role in almost 
every aspect of the malignant haematological development. Plasma from patients 
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with a haematological malignancy contain much higher numbers of exosomes 
compared to that of normal origin (Szczepanski et al. 2011). In AML and CML these 
high numbers at diagnosis change once the patient begins therapy and a reduction 
in exosomal protein is observed in line with treatment, and in AML shows a correlation 
with leukaemic blast reduction. AML patients that achieved long term remission over 
two years saw plasma exosomal levels return to those seen in normal samples, 
reflecting the potential use of exosomes as a measure of disease and also an 
indicator of relapse (Hong et al. 2014b). 
In AML, CML and MM exosomal derived nucleic acid content is linked to that of the 
parental cell, RNA from AML derived exosomes were shown to express AML 
prognostic markers NPM1 and FLT3-ITD (Huan et al. 2013). In miRNA from CML 
derived exosomes high levels of CD19 were shown signifying it’s leukaemic B-cell 
origin (Ghosh et al. 2010). The miRNA and small RNA content carried by leukaemic 
cell line exosomes shows a greater level than that seen in the parental cells. miRNA 
of MM MSC-derived exosomes showed higher expression levels of oncogenic mIRs, 
and lower expression of tumour suppression mIRs compared to those from normal 
MSC-derived exosomes (Huan et al. 2013; Roccaro et al. 2013). This supports the 
theory that exosomes play an important role in the transfer of oncogenic material and 
the subsequent spread of haematological malignancy.  
Exosomes have also been implicated in therapy resistance as described by a recent 
study using adoptive cell therapy (ACT) of activated NK cells as a form of 
immunotherapy in AML. This study produced disappointing results due to AML 
derived exosomes reprogramming NK-92 cells by delivering multiple inhibitory 
ligands to the receptors expressed on the cells, activating multiple suppressive 
pathways in NK92 which interfered with their anti-leukaemic function and reduced the 
overall therapeutic potential of the ACT(Hong et al. 2017) . 
The therapeutic use of exosomes in recent years has become popular and they are 
currently being used in clinical trials as anti-cancer vaccines. Exosomes themselves 
have been identified as a potential inhibitory target as their numbers are often 
increased in correlation with severity of cancer. A certain component associated with 
the modulation, formation or release of exosome uptake is usually inhibited, an 
example of this is the Rab family of proteins implicated in exosome secretion. The 
disadvantage of such exosome inhibitors are their lack of specificity and critical role 
in all endosomal trafficking within cells leading to off target effects and high toxicity in 
patients (Datta et al. 2018). Exosomes are also being considered as a good way of 
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transporting drug or gene therapies into target cells as they are small and able to 
cross many biological barriers unimpeded. They commonly contain many adhesion 
associated proteins on their cell surface, and have low toxicity and immunogenicity 
due to their endogenous origin making them ideal for delivery (Tian et al. 2014b; Yang 
et al. 2015). 
Due to their ubiquity within the human body and the correlation seen between 
circulatory levels and disease prognosis they have great potential use as a diagnostic 
biomarker for disease. Studies have shown that exosome biomarkers are known to 
perform better as a cancer diagnostic compared to biomarkers sourced from other 
liquid biopsy such as plasma, this could be due to the contents encasement within a 
protective barrier helping to  withstand laboratory analysis techniques e.g. 
freeze/thaw and give a more stable readout (Wong and Chen 2019). 
Current research in haematological malignancy has not explored the effect of stromal 
derived exosomes  on cell to cell communication within the bone marrow environment 
and the preferential support provided to the AML cells that reside there. The potential 
mechanisms driving this support are unknown and forms the basis of this research. 
 
1.10 Hypothesis 
This study will investigate the hypothesis that exosome mediated communication is a 
contributing factor for the survival of residual AML blasts in the bone marrow niche. 
Monitoring of exosome content may identify molecular changes that have a functional 
affect in AML patient samples that could potentially be used to detect disease 
progression. 
1.11 Study Aims 
Within haematological malignancy the bone marrow microenvironment is a key player 
in mediating chemotherapy resistance and providing a sanctuary site from which 
leukaemic cells can evade chemotherapy, suppress immune response, produce 
disease resurgence and relapse.  
Currently, residual disease within AML is unlikely to be overcome by pharmacological 
drug intervention and BM-transplant is still the most effective form of treatment for 
poor-risk patients, unfortunately there is still a high rate of relapse within this patient 
sub-set and subsequently this unmet clinical need forms the basis of my research. 
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AML patient samples are heterogeneous in nature but currently the associated risk 
factors such as molecular profile, FAB type and drug response at diagnosis do not 
fully explain the disparity observed between patient response post-transplant, making 
it difficult for clinical decisions to be made regarding patient treatment going forward. 
Bone marrow transplant is a complicated procedure with many factors influencing 
patient outcome. Serial sampling of patients in order to monitor changes that precede 
relapse rather than a comparison between patients, could potentially help overcome 
heterogeneity issues and identify targets linked to increased disease progression and 
potentially in the long term aid clinical decisions for patients that respond unfavorably 
post- transplant.  
Exosomes secreted by the MSCs of the BM-niche are known to have an important 
role as message delivery vehicles but the impact they have in mediating cross-talk 
following post-BMT in AML is relatively unknown.  
The aim of this project is to identify functional behaviours and potential biomarkers 
through MSC derived secretory profiling of exosomes, cytokines and miRNA from a 
range of disease stages 
The aims are as follows: 
1. To isolate AML-derived MSC cultures and quantify exosome production 
across a range of normal and disease states. 
2. To characterise exosome contents at the miRNA and protein level and 
compare disease stages.  
3. To assess the functional effects of MSC exosomes on AML cell within  a 
stromal co-culture model. 
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2 Chapter 2. Materials and Methods 
2.1 Composition of Stock Solutions 
All reagents and plasticware were obtained from Sigma Aldrich UK Ltd (Dorset, UK) 
or Fisher Scientific UK Ltd (Loughborough, UK) unless otherwise stated. 
2.1.1 Western Blotting Reagents 
Cell lysis buffer (stock): 1.5ml 5M NaCl, 1ml 1M Tris buffer (pH 7.4), 5ml Glycerol, 
0.5ml Igepal NP40, 1ml 0.5M EDTA, 5ml 1M NaF, 30ml ddH2O  
Cell lysis buffer (working): 1 MiniComplete EDTA free tablet (Roche) dissolved in 
1ml ddH2O, 8.7ml lysis buffer stock, 300µl 0.1M Sodium orthovanadate (New 
England Biolabs, Massachusetts, U.S.A), 1% Triton X-100 
Running buffer: 950ml ddH20, 50ml 3-(N-morpholino) propane sulphonic acid 
(MOPS) running buffer (Invitrogen Ltd, Paisley, UK)   
Transfer buffer: 100ml methanol, 1ml NuPage antioxidant, 50ml transfer buffer 
(Invitrogen Ltd, Paisley, UK), 849ml ddH20 
Blocking buffer: 5% and 2% w/v TBS-T, milk powder  
TBS-T: 10ml 1M Tris (pH 7.4), 20ml 5M NaCl, 10ml 10% Tween-20, 960ml ddH20  
2.2 Tissue Culture Reagents 
MEM dilution medium: MEM, Penicillin/Streptomycin, 20µM/ml Heparin sodium (CP  
Pharmaceuticals) 
Primary cell culture medium: IMDM: Dulbecco’s medium, HEPES buffer, sodium 
bicarbonate, 200mM L-glutamine, 10% Foetal calf serum (FCS) (Labtech Int. Ltd., 
U.K), Gentamicin (50µg/ml) 
HS5 culture medium: DMEM (high glucose),10% Glutamax, 10% FCS, Gentamicin 
(50µg/ml)  
MV411 culture medium: IMDM medium, 200mM L-glutamine, 10% FCS, Gentamicin 
(50µg/ml)  
KG1a culture medium: RPMI medium, 200mM L-glutamine, 20% FCS, Gentamicin 
(50µg/ml) 
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MSC culture medium: DMEM (low glucose) medium, 200mM L-glutamine, 15% 
FCS, Gentamicin (50µg/ml)  
Flow cytometry staining buffer: 0.5% BSA, 1x PBS, 0.02% Na Azide  
TBS: 0.01M Tris (pH 7.4), 20ml 5M NaCl, 970ml ddH20  
7AAD staining buffer: 1μg/ml diluted in PBS 
2.2.1 FCS serum batch testing 
FCS contains a complex mixture of components which may vary according to origin, 
nutritive conditions and processing. Because of this natural variation it is necessary 
to do batch testing, this consists of assessment of the growth support level of the 
serum of commonly used cell lines.  
The cell lines HS5, MS5, KG-1a, and MV411 were harvested when in log phase of 
growth and resuspended at 4-8 x105 cells/ml in medium supplemented with different 
FCS batches. Cells were seeded within a 96-well tissue culture plate and placed into 
37oC incubator for 48 hours. Cells were harvested and cell viability assessed using 
7-AAD and flow cytometry (see section 2.6). Cell viability was compared between 
batches to check no significant difference exists.   
2.3 Antibodies 
2.3.1 Antibodies Used in Flow Cytometry 
All flow cytometry antibodies were sourced from Biolegend Inc. (San Diego, U.S.A) 
and used at a concentration detailed in section 3.2.2. 
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2.3.2 Antibodies Used in Western Blotting 
 
Table 2. 1 Summary of antibody details used in western blot and ELISA analysis 
2.3.3 Antibodies used in ELISA assay 
ALIX, TIMP-1 and IGFBP3 antibodies used at 1μg/ml, supplier detailed above in 
Table 2.1.   
2.4 Tissue Culture 
The following experiments were carried out in class II laminar flow biological cabinets 
on work surfaces sterilised with 70% ethanol prior to commencing work. All materials 
used in tissue culture were either purchased sterile or filter-sterilised prior to use and 
contaminated waste was disposed of using an autoclave. 
2.4.1 Primary cells – Freezing and Thawing 
Bone marrow samples were obtained at the University Hospital of Wales and normal 
marrow donors were obtained from Welsh Blood Service under specific ethical 
approval REC: 17/LO/1566, IRAS project ID:231974. All patients gave informed 
consent in accordance with the declaration of Helsinki and excess material was stored 
for research purposes and samples were collected in  EDTA vacutainer tubes. A 
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nucleated cell count was performed on a 40µl aliquot of sample diluted in 20ml Isoton 
II diluents using a Coulter Z2 Particle Count and Size Analyzer (Beckman Coulter). 
6-7ml aliquots of patient sample were layered over equal volumes of Ficoll-
Histopaque 1077 using a syringe with 0.8mm aluminium hub needle. Samples were 
diluted according to the baseline count with warmed MEM dilution medium and FCS 
to give a maximum of 100x106 nucleated cells per Ficoll gradient. Following ficoll 
separation, mononuclear cells within the interface were removed and this suspension 
was washed twice in dilution medium, and the monolayer pellet was re-suspended in 
500µl MEM dilution medium and pooled in a universal container. A further nucleated 
cell count was then performed. Mononuclear cells, suspended in MEM dilution 
medium, were divided into 500μl aliquots in 1.8ml cryovials, to ensure a maximum of 
100x106 cells per vial. 400µl FCS and 100μl dimethylsulphoxide (DMSO) was added 
dropwise slowly to each vial and swirled. Cryovials were then transferred to a freezing 
container half filled with propan-1-ol and placed at -80°C overnight to ensure 
controlled-rate freezing. Cryovials were then moved to liquid nitrogen for long-term 
storage.  
Cells were recovered from liquid nitrogen and 20µl DNase (10µg/ml) was added to 
the vial followed by 900µl of sterile 0.45µm filtered FCS, cells were then transferred 
to a 37oC water bath for 3 minutes incubation. Vials were removed, swabbed with 
alcohol and carefully transferred to a universal container, a doubling volume of IMDM 
complete medium was then added dropwise over three minute intervals in triplicate 
to prevent osmotic damage up to a volume of 14ml, cells were then centrifuged at 
1000rpm for 10 minutes prior to resuspension in MEM complete media at a 
concentration of 5x106/ml for further analysis. 
2.4.2 Cell Viability Assessment 
Prior to spinning, an aliquot of cells was removed for counting, mixed 1:1 volume with 
0.4% w/v Trypan Blue viability stain and cells counted by light microscopy using Fast-
Read Disposable Counting Chambers (Immune Systems Ltd), where live cells 
exclude the Trypan blue stain and dead cells stain blue and a minimum of 200 cells 
counted. Cell viability was expressed as a percentage of live cells from total number 
of cells: 
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2.4.3 Cell culture maintenance 
MSC vials were thawed as previously outlined in 2.4.1 and allowed to form stroma 
typically taking 4-6 weeks to reach confluence following a 24 hour recovery period 
where any AML cells still in suspension would be removed (Figure 2.1) Medium 
change was carried out once a week by removing half medium and replacing with 
fresh. Cells were split once confluent by removing medium, washing with sterile 1x 
PBS, 5-7ml of Accutase added to a T75 tissue culture flask and placed in 37ºC 
incubator for no more than 10 minutes in order to remove cells. Cells were then spun 
at 1200rpm, supernatant removed, pellet resuspended, and cells counted before 
seeding into fresh tissue culture flask.   
 
Figure 2. 1. Overview of primary AML derived MSC monolayer cell culture production. 
HS5 cells were not used above passage 4 due to acquisition of culture associated 
genetic and differentiation changes. HS5 cells form a stromal monolayer quickly post-
thaw and harvest of cells is carried out by first washing the cells with sterile 1xPBS 
after removing medium and then adding 5-7ml Trypsin-EDTA to a T75 tissue culture 
flask and incubating in a 37oC incubator for ~ 5 minutes. Cells easily dissociate from 
the base of the flask base by pipetting 10ml of medium into flask and swirling. Cells 
were then transferred to a universal tube and centrifuged at 1200rpm, then counted 
and seeded at 1x105 cells/ml to be used at 80-90% confluency the following day.  
Primary AML cell growth is sample dependent, cells are given a 24-hour recovery 
period post-thaw and seeded at a density of 7.5x105 cells/ml for experimental assays. 
Cells are split when required and medium changed 1-2 times a week by removing 
supernatant, centrifuging at 1200rpm, pellet resuspended in fresh medium and 
reseeded in fresh tissue culture flask.  
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MV411 and KG-1a cells are split 1-2 times a week as outlined for primary material, 
they are seeded at 0.5x105 cells/ml for experimental use and kept at 1-10x105 cells/ml 
confluency for maintenance.    
2.5 Exosome Isolation 
2.5.1 Collection of exosomes 
Exosome free medium was produced in advance and prepared by making up growth 
medium containing double serum concentration plus usual additions of L-glutamine 
and gentamycin. Medium was ultracentrifuged at 100,000 x g for 17 hours at 4°C, 
aspirated off leaving pellet and then passed first through a sterile filter of 0.4µm then 
secondly a 0.22µm filter. Medium could then be made up to the working concentration 
of serum using serum free medium and added to culture when cells were close to 
confluency. Cells were always washed with serum free medium before exosome free 
medium was added to remove any residual serum derived exosomes.  
2.5.2 Ultracentrifugation exosome isolation 
Exosome containing medium was removed from tissue culture flasks and pooled into 
50ml falcon tubes and cells spun at 2000 x g at 4ºC for 20 minutes, supernatant was 
removed placed into fresh tube and spun at 10,000 x g at 4ºC for 30 minutes, 
supernatants could then be stored at -80°C until ready for next stage of procedure. 
Supernatant was transferred to a thin wall polypropylene tube (Beckman Coulter, 
High Wycombe, UK) and ultracentrifuged at 100,000 x g at 4ºC for 60 minutes (SW-
28 rotor, Beckman Coulter, High Wycombe, UK). Partially purified exosome pellet 
was underlain with 4ml of 30% sucrose/D2O (density of 1.2 g/ml) and ultracentrifuged 
at 100,000 x g for 75 minutes at 4oC. Approximately 2 - 3ml of the central base of the 
sucrose cushion solution was collected and diluted in excess sterile 1 x PBS. The 
exosomes were pelleted by ultracentrifugation again at 100,000 x g for 70 minutes at 
4oC and pellets were resuspended in 50µl of sterile 1xPBS and stored at -80oC, until 
required for further experimental use.  
2.6 Flow Cytometry 
Flow Cytometry was performed using a Becton-Dickinson Accuri C6 cytometer 
coupled to a Dell Optiplex 765 Personal Computer running C-Flow Plus software for 
data acquisition and analysis.  
2.6.1 Immunophenotyping 
1x105 MSC cells were detached using accutase to preserve cell surface markers and 
washed before being placed in a universal container and centrifuged at 1200 rpm for 
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5 minutes, supernatant was removed and re-suspended in 40μl of ice cold staining 
buffer and 20μl of this suspension was placed in duplicate in a 96-well V-bottom plate. 
10μl of antibody (see Table 3.2) were added to each well to give a total volume of 
50ul per well. In the second well 10μl of the relevant anti-IgG1 isotope control for 
APC, PE and FITC was added. The plate was covered and vortexed gently and 
incubated at 4°C for 30 minutes. 150μl of cold staining buffer was added to stop the 
reaction and the plate was centrifuged at 1200 rpm for 3 minutes and the supernatant 
aspirated. Cell pellets were re-suspended in 50µl 1ug/ml 7AAD/FACS buffer for 
viability staining and this suspension was transferred to flow tubes for analysis where 
a minimum of 10,000 live events were recorded. Using C-Flow software, live cells 
(7AAD negative) were gated and CD45 was used to determine myeloid, lymphocyte 
and stromal fractions present at each passage with addition specific markers for 
target populations quantified using % positivity.    
2.6.2 Cell proliferation assessment 
Cells were harvested following assay incubation and if co-cultured with HS5 cells 
these were harvested separately. Cells were centrifuged in either a 15ml falcon tube 
or a V-well 96-well plate (depending on scale of assay) at 1200rpm for 5 minutes at 
4ºC following 50µl addition of Absolute CountBright beads (ThermoFisher Scientific) 
per sample. Protocol was followed as above (2.6.1) using CD45 APC to differentiate 
HS5 cells from the rest of the cell population. At least 1000 bead events were acquired 
per sample and appropriate gating strategy used for analysis.  
2.7 Western Blotting 
2.7.1 Sample preparation and protein quantification 
Exosome and whole cell cell lysates were prepared by adding 10μl of exosome 
preparation/cell pellet to 25µl of cell lysis buffer, mixed by vortex and incubated on 
ice for 30 minutes, samples were vortexed at 10 minute intervals during incubation. 
Following incubation samples were centrifuged at 1200rpm for 5 minutes to pellet 
debris and supernatant transferred to fresh 1.5ml Eppendorf tube and stored at -80°C 
until use. 
2.7.2 Bradford Protein Assay 
Bradford assay was set up in a MaxiSorp 96-well flat bottom plate (ThermoFisher 
Scientific), 10µl standards were prepared in advance using BSA and sterile water at 
0,10,40,70 and 100μg/ml concentration and aliquoted in triplicate with 1µl of lysis 
buffer spiked into each standard to compensate for detergent interference. Bradford’s 
stock solution was made up to working solution by diluting 1:1 with sterile water and 
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190µl added to all wells. The absorbance of the solutions was measured by reading 
the plate on a spectrophotometer at 590nm and protein content of exosome 
preparation calculated in µg/ml using the standard curve and appropriate dilutions. 
2.7.3 Western gel electrophoresis 
Unless stated separately, all pre-prepared reagents and materials used in western 
blotting including NuPage gels, LDS loading buffer, sample reducing agent, 
antioxidant, 3-(N-morpholino) propane sulphonic acid (MOPS) running buffer, 20x 
transfer buffer, Magic Mark XP Western Protein Standards and polyvinylidine 
difluoride (PVDF) membranes were supplied by Invitrogen Ltd (Paisley, UK). XCell 
SureLock Mini-Cell electrophoresis tank and XCell II Blot Module were also supplied 
by Invitrogen.  
Samples were incubated in a heat block at 70°C for 10 minutes then quenched on ice 
for 1 minute before being loaded into pre-cast NuPage 4-12% Bis-tris gel (1mm 12 
well) NP0322 (Life Sciences). Wells of the gel were previously washed in sterile water 
and running buffer with added antioxidant (200ml running buffer + 500µl NuPAGE 
antioxidant). Gels were run with MagicMarker molecular weight ladder (Life Sciences) 
at 200V constant for 50 minutes.  
2.7.4 Western blot transfer 
During electrophoresis a pre-cut nitrocellulose membrane (0.45um pore size) and 
filter paper sheets were pre-soaked in transfer buffer together with sufficient blotting 
pads to fill the transfer module. The gel was removed from the tank and after careful 
removal of the stacking gel a sandwich of blotting membrane, filter paper and pre-
soaked blotting pads were constructed around the gel and the transfer module was 
filled with transfer buffer (Figure 2.2) The surrounding outer chamber was filled with 
ddH20 and run at 30V constant for 1 hour. 
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Figure 2. 2 Blotting apparatus for western blotting  
2.7.5 Immunodetection 
At the end of transfer the gel was removed and washed twice in 20ml ddH20 for 5 
minutes. It was then incubated in 10ml 5% blocking buffer for 1 hour followed by 
washing in TBST for 30 minutes at 6 x 5 minute intervals. After this time the primary 
antibody was added, made up in 10ml 2% blocking buffer and diluted according to 
the manufacturer’s instructions and incubated overnight on plate shaker at 2-8°C.   
Following incubation, the membrane was rinsed twice in TBST and then washed at 5 
minute intervals for 30 minutes, it was then incubated in rabbit or mouse secondary 
antibody at 1:25000 in 2% blocking buffer for 60 minutes. After this time the 
membrane was washed at 5 minute intervals for 30 minutes and developed with 
Chemiluminescent Substrate ECL Select (VWR, Pennsylvania U.S.A) for 5 minutes. 
Finally, the membrane was processed on the LAS-3000 imager for a period of time 
determined by the strength of the signal ranging from 1-60 minutes. 
2.8 Luminex Analysis 
2.8.1 Sample preparation 
Exosome preparations were lysed using a cell extraction buffer (see recipe below) 
which was made in advance, aliquoted into 10ml tubes and stored at -20°C. Before 
use, one protease inhibitor tablet (Roche, IN, U.S.A) and 1mM PMSF was added and 
stored at 4°C for up to 4 weeks. 10µl of exosome preparation was added to 25µl of 
2x Luminex cell extraction buffer and standard lysate protocol was followed as 
outlined previously (2.7.1). 
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2x Cell Extraction Buffer: 10mM Tris pH 7.4, 2mM Na3V, 100mM NaCl, 1% Triton 
X-100, 1mM EDTA, 10% Glycerol, 1mM EGTA, 0.1% SDS, 1mM NaF, 0.5% 
Deoxycholate, 20mM Na4P2O7. 
Exosome samples prepared in this extraction buffer had to be diluted 10-fold to avoid 
interference within the Luminex run, I diluted all of my exosome lysates for Luminex 
analysis using the Luminex cell extraction buffer to equalise to a concentration of 
20µg/ml, they were then diluted within the 96-well test plate to a final concentration 
of 2µg/ml.  
2.8.2 Luminex analysis 
For all of the following analysis Magnetic Luminex Assay: Human Premixed Multi-
Analyte Kit (R&D Systems Inc., Oxford, U.K) was used. 104 cytokine and chemokine 
targets were multiplexed over three luminex bead array panels, these included 
several known MSC derived candidates which have previously been described 
(FLT3, GAS6, FGF2, EGFR, IL-8, TIMP-1, TGF-β, TNF, CCL3, MCP-1 (Huang et al. 
2015; Corrado et al. 2016) and have suggested links to disease progression as well 
as other targets whose functional consequences are unknown within the post-
transplant setting and cover a variety of biological processes including survival, 
differentiation, immunology, chemoattract and adhesion. All reagents were brought 
up to room temperature and standards were provided with the kit but varied in number 
depending on the analytes selected. Each standard was reconstituted with Calibrator 
Diluent, volume added was dependent on number of standards provided. Standards 
were multiplexed and a serial dilution was then carried out to produce a 3-fold dilution 
series using 100μl of standard and then 200μl diluent, tubes were mixed thoroughly 
between transfers and a calibrator diluent blank was included. 
Diluted microparticle cocktail, biotin-antibody cocktail and streptavidin-PE were all 
prepared according to kit instructions. 50μl of sample and standard were added to 
designated wells of a 96-well plate and 50μl of microparticle cocktail was added on 
top, a foil lid sealed the plate and it was placed on a shaker set at 800rpm for 2 hours 
at room temperature. 
After incubation a magnetic device was used to wash the plate with 100μl of wash 
buffer, leaving for 1 minute then removing and repeat this washing process three 
times 50μl of biotin-antibody cocktail was added to each well, covered with foil plate 
sealer and incubated on plate shaker set at 800rpm for 30 minutes. 
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Plates were washed as previously described and 50μl of streptavidin-PE was added 
to each well, sealed and incubated on shaker set at 800rpm for 30 minutes. 
During this incubation period the Luminex Analyzer was set up by switching on to 
warm up then running calibration programme which uses highly purified recombinant 
human biomarkers to ensure the system is operating correctly and maintain data 
accuracy. Instrument settings were inputted, these included assigning the 
microparticle region for each analyte being measured. 
Plates were washed as previously described and microparticles resuspended in 100μl 
of wash buffer to each well, the plate was incubated on shaker set at 800rpm for 2 
minutes and then read using Luminex 200 Analyzer instrument. 
2.9 Permeabilised Exosome ELISA Assay 
Exosomes were diluted in PBS and bound onto a high protein binding ELISA strip 
plate (Greiner Bio-One) at a dose of 1µg/well and incubated overnight at 4oC. Wells 
were washed three times using a wash buffer (Kaivogen), to remove unbound 
particles and then blocking solution (1% BSA/PBS, w/v) was added for 2 hours, before 
washing three times. Radioimmunoprecipitation assay (RIPA) lysis buffer (Santa 
Cruz, Texas, USA) was added for 1 hour at RT, before being washed three times. 
Primary antibodies were added at 1µg/ml (2.3.3), for 2 hours at RT. After washing 
wells three times, the primary antibodies were detected by goat anti-mouse 
biotinylated antibody (Insight Biotechnology) (diluted in 0.1% BSA/PBS, w/v), at a 
200ng/ml working concentration for 1 hour at RT. The wells were washed three times, 
before adding a europium-streptavidin conjugate (Perkin Elmer) in assay buffer 
(Kaivogen) for 45 minutes at RT. The wells were washed six times, before adding 
enhancement intensifier (Kaivogen) for 5 minutes at RT and signal assessed by TRF 
on a PHERAstar FS Microplate Reader (BMG Labtech). 
2.10 Statistical Analysis 
All standard statistical analyses were performed using Prism-6 Software V6.07 
(GraphPad, San Diego, USA). Luminex data analysis (PCA and hierarchical charts) 
were carried out using Partek Genomics Suite (Partek Inc, Missouri, USA). All 
experiments were performed in triplicate. In experiments with more than two 
experimental groups, 1-way ANOVA was used with Kruskal-Wallis post-test to further 
investigate variability between groups. When comparing two experimental groups 
evaluation was carried out using Students t test for cell line experiments with 
parametric data spread and Mann-Whitney U (for non-parametric primary AML 
experiments) to compare ranks; a particularly robust analysis for data sets that 
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contain outliers. P-values less than 0.05 were considered significant and graphs 
depict mean +/-SEM three similar experiments unless otherwise stated. 
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3 Chapter 3: Isolation and Characterisation of 
Extracellular Vesicles 
3.1 Introduction 
3.1.1 Exosome definition and identification 
Exosomes are the smallest sub-category of extracellular vesicles and have been 
implicated in numerous cancer studies as a major contributor within the cell to cell 
communication network acting as delivery vehicles of various soluble factors 
including miRNA, proteins and lipids known to aid pathological processes including 
malignant transformation. Due to their small size they have an advantage over the 
larger sub-category of extracellular vesicles as they are able to travel further and 
cross major biological barriers going relatively undetected by immunosurveillance as 
well as being more easily assimilated by acceptor cells, this has made them an ideal 
candidate for targeted gene/drug delivery, a popular clinical strategy in recent years. 
Previous studies in AML have shown that plasma originating from diagnostic AML 
patients contains higher levels of exosomes compared to that of normal plasma (Hong 
et al. 2014a), however the content and number of exosomes released within AML 
patients at different stages of treatment and particularly in the post bone marrow 
transplant (BMT) environment has not yet been well characterized and forms the 
basis of my investigations. 
Previous work has shown that cancer derived exosomes can contribute to the 
progression of cancer by aiding the intercellular transfer of protein, lipid and nucleic 
acid cargo within the malignant microenvironment. Numerous oncological studies 
have shown that malignant cells secrete higher numbers of exosomes compared to 
healthy cells and the cargo they transport also differs (Al-Nedawi et al. 2008; Skog et 
al. 2008; Luga et al. 2012; Peinado et al. 2012). 
Exosomes harvested from urinary samples from cancer patients have been used to 
identify protein markers such as  the EGFR pathway, α-subunit of GsGTP binding 
protein, resistin and retinoic acid induced protein which are absent in healthy 
individuals (Smalley et al. 2008). Pancreatic cancer patients have shown the 
presence of Glypican-1 (a cell surface proteoglycan) on exosomes derived from 
patient serum in both early and late stages of disease, which was absent in benign 
samples (Melo et al. 2015). Work on ovarian cancer has shown that when exosomes 
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from diseased patient plasma are compared to benign or normal, higher levels of 
exosomes were seen along with the presence of TGF-β1 and MAGE3/6 protein 
markers. In addition to higher exosome levels in diagnostic samples compared to 
normal, exosome increases are also  observed with disease progression (Szajnik et 
al. 2013). 
Research has shown that miRNA signatures for exosomes derived from cancer 
patients do not always correspond to that of the parental tumour cell (Nolte-'t Hoen et 
al. 2012), it has been suggested that the miRNA that exosomes carry is selected, 
sorted and directed by the parental cell to specifically targeted recipients (Ciardiello 
et al. 2016). Disease specific miRNA profiles derived from exosomes have been 
identified in  a wide variety of cancers including colorectal, lung and breast (Roberson 
et al. 2010; Corcoran et al. 2011; Cazzoli et al. 2013; Ogata-Kawata et al. 2014). 
Disease progression and therapeutic response has also been linked to expression of 
miRs such as miR-21 which is overexpressed in exosomes originating from ovarian 
and cervical cancer cells and correlates with increased disease progression (Taylor 
and Gercel-Taylor 2008; Liu et al. 2014). 
The nomenclature of extracellular vesicles is constantly being developed and refined 
within the research community, but the following two characteristics are universally 
accepted as exclusive to the exosome subcategory of microvesicles: 
A. Particle within the size range of 30-100nm 
B. Generated by inward budding of endosomal multivesicular bodies and release 
via fusion with the plasma membrane 
Recent work using asymmetric flow field fractionation (AF4) technology which 
separates particles based on their density and hydrodynamic properties has identified 
a further sub-population of exosomes, large exosome vesicles (90-120nM) and small 
exosome vesicles (60-80nM) alongside an abundant population of non-membranous 
nanoparticles (~35nM) named ‘exomeres’. Exomere profiling revealed the presence 
of various proteins involved in pathways such as glycolysis and mTOR signalling. The 
large and small exosomes showed the presence of lipid, protein, DNA and RNA 
species (Zhang et al. 2018).   
Identification of exosomes using an associated protein marker is difficult, there is no 
single reliable marker as any cargo carried on the exosome membrane must have 
originated from the endosomal membrane, and anything inside would have come 
from the cytosol, meaning that even though the cargo might carry more of a certain 
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molecule within the exosome, it is not exclusive to it. Typically, a combination of 
markers is used, for example the tetraspanins (CD63, CD81, CD82)  known to be 
enriched within the exosome membrane, proteins associated with ESCRT machinery 
(TSG101), cytosolic proteins associated with exosomes (GAPDH) and antigen 
presenting molecules (MHC) are all cellular components that make up the molecular 
composition of an exosome. 
Characterisation of exosomes is an area of ongoing research which is required in 
order to standardize assessment criteria. Updates to guidelines and criteria for 
defining extracellular vesicles are published every four years by the International 
Society for Extracellular Vesicles, the most recent publication was 2018. 
General characterization of extracellular vesicle preparations should follow the 
guidelines outlined by the Society of Extracellular Vesicles as follows: 
1. Presence of at least three protein markers including: 
a) Transmembrane/lipid bound protein 
b) Cytosolic protein 
2. Characterization of single vesicles preferably using both of the following 
techniques: 
a) Electron or atomic force microscopy 
b) Single particle analyzers 
3. Quantification of vesicle preparation, of which there is no single preferential 
method, total protein and total particle number is most commonly used. Both 
components are not exclusive to vesicles, proteins are soluble, and particles 
can be aggregates so a measure incorporating both in the form of a ratio of 
protein: particle is recognised as the most reliable measurement of EV 
preparation purity. 
 
3.1.2 Overview of exosome isolation and methodologies 
Isolation of exosomes is difficult to achieve due to similarities in the biophysical 
characteristics between exosomes and extracellular vesicles within the same size 
range, most preparations will most likely contain a mixture of small EVs which is why 
some prefer to use the term ‘small extracellular vesicles’ instead of exosome. Many 
factors including cell type and environmental conditions can influence the content of 
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the exosome preparation and most current isolation protocols will produce a mixture 
of exosomes, extracellular vesicles of non-endosomal origin, lipid-based non-
vesicular structures, lipoproteins and exomeres.  
There are several different isolation techniques which can be used depending on the 
degree of exosome purity and concentration required, a summary of the frequently 
used methods is as follows. 
1. Ultracentrifugation 
This is the most commonly used technique to isolate extracellular vesicles and is 
considered the gold standard of exosome isolation due to the relatively minimal long 
term running cost and technical expertise needed, along with the low levels of 
contaminating vesicles present in the resulting prep. Different centrifugal forces 
sediment particles according to density, size and shape, the centrifugal force ranges 
from 100,000 to 120,000 x g. Initial low speed spins are used to separate out dead 
cells and debris, then a series of high speed runs between which the supernatant or 
pellet is resuspended until finally the exosomes are isolated and resuspended in 
appropriate buffer and stored. Alternative steps can be added to the 
ultracentrifugation protocol to increase the purity of the sample although this comes 
at the sacrifice of exosomal yield. A sucrose cushion step can be added onto which 
the sample is layered and following centrifugation, the exosomes in the sample 
separate out into discrete zones due to their different densities and can then be 
recovered by simple fraction collection. This step will eliminate contaminants such as 
non-specific proteins or large protein aggregates which are sedimented out but do 
not float on the sucrose gradient. 
2. Size exclusion  
Exosomes are separated based on their size or molecular weight and passed through 
a physical barrier using chromatography or filters, one of the popular exosome 
isolation techniques is ultrafiltration which follows the same format as standard 
filtration but with the additional use of applied force. Usually a 0.8μm filter is used 
initially to remove cell fragments then a 0.2μm filter is used to isolate exosomes. To 
enrich the exosome preparation further, filtering steps using low-molecular weight 
filters can be used. Although ultrafiltration is a much quicker process than standard 
filtration, it has since been reported that forcing particles through filters can lead to 
particle deformation which may affect their use in functional assays (Witwer et al. 
2013). 
55 
 
3. Immunoaffinity Isolation 
This isolation technique uses the presence of specific surface proteins associated 
with exosomes using antibodies to immune-enrich or deplete samples. Antibodies are 
usually associated with beads or other matrices and physical separation takes place 
following low-speed centrifugation or magnetic technique, there are several 
commercially available kits based on the concept of magneto-immunocapture. 
Immunological techniques are highly specific in their isolation of exosomes and in 
some cases are regarded as a superior method to ultracentrifugation although at the 
cost of much lower yields. Therefore, these methods are most beneficial when used 
in combination with other techniques in order to further purify and enrich the exosome 
preparation. 
4. Polymeric precipitation 
Exosome containing solutions are incubated with a precipitation solution containing 
water-excluding polymers, following overnight incubation the exosomes are 
precipitated out of solution and are further isolated using low-speed centrifugation or 
filtration. There are a number of commercially available exosome precipitation kits 
available and they are very quick and easy to use with minimal specialist equipment 
needed, results have shown high yields of RNA but a number of non-exosome 
contaminants such as proteins and polymeric materials have been seen to co-
precipitate with the exosomes resulting in an exosome preparation which is highly 
likely to contain high levels of contaminating particles. 
5. Microfluidics 
The most recent development in exosome isolation, microfluidic devices are 
manufactured to use both biochemical and physical characteristics to isolate using 
electrophoretic and electromagnetic mechanisms. Microfluidic devices can trap 
exosomes and filter out unwanted proteins, larger extracellular vesicles and cell 
debris using immunoaffinity, size and density. The specificity of these devices can be 
enhanced using immunoaffinity capture within the microfluidics to isolate specific 
exosomes. The advantage of these devices is the low volume of input material and 
reagent needed and preparation time very low, although the application of these 
methods within biological fluids has not been extensively investigated so far (Li et al. 
2017).  
Table 3.1 summarises the pros and cons of the current most popular exosome 
isolation techniques. 
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Table 3. 1 Summary of exosome isolation techniques 
The isolation and characterisation of exosomes is an important area of research 
which is constantly being updated. In order to adequately facilitate research and 
potential clinical applications, development is necessary to successfully isolate, 
subtype and quantify total exosome populations. Choice of methodology will depend 
primarily upon both downstream applications and source material, these are 
important factors to assess before selecting a technique. 
3.2 Methods 
3.2.1 Culture of mesenchymal stem cells 
According to the methods described in Chapter 2 MSC cultures were cultured and 
once reached confluency, adherent MSCs were detached using 5ml of TrypLE 
Express and incubated for no longer than 5 minutes in a tissue culture incubator. 
Once cells were detached and counted ~1-2x106 cells were frozen down for future 
use according to methods outlined in Chapter 2, (these cells were classified as 
passage 1 (P1)). 1x105 cells were set aside for immunophenotyping and the rest split 
into two T75 flasks, fresh growth medium added and expanded for 2 weeks. Cells 
were sub-cultured until confluent and the process repeated until passage 3 for use in 
subsequent assays. MSCs cultured further beyond P4-5 are known to induce genetic 
and differentiation culture-related changes (Bonab et al. 2006). 
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3.2.2 Immunophenotyping of stromal cultures 
MSCs were collected following every sub-culture to passage 3, 1x105 cells were 
centrifuged at 1200rpm to form a pellet, supernatant removed and resuspended in 
appropriate volume of ice-cold staining buffer. Cell suspension was added to 8 wells 
of a 96-well V-bottom plate, centrifuged for 1200rpm for 3mins, aspirated and 50µl of 
each of the antibody cocktails shown in Table 3.2 were added to the appropriate well, 
mixed and incubated at 4°C for 30 minutes. The addition of 100µl of cold staining 
buffer ended the reaction, the plate was centrifuged at 1200rpm for 3 minutes and 
cells were resuspended in 100µl of 1µg/ml 7AAD solution in order to assess cell 
viability. Flow cytometry was used to analyse samples, a minimum of 5000 live events 
were recorded using the BD Accuri Cytometer. C-flow software was used to analyse 
samples using gating appropriate to the fluorescent labelling used within each 
antibody cocktail and expression levels of each target was quantified by mean 
fluorescence intensity. 
 
 APC (FL4) FITC (FL1) PE (FL2) 7AAD (FL3) 
1 CD45 CD44 CD90 + 
2 CD45 CD14 CD34 + 
3 CD45 CD29 CD73 + 
4 CD105 CD45  + 
5 CD71 CD45  + 
6 CD45 CD31 Nestin + 
7 CD324 CD146  + 
8 IgG IgG IgG + 
 
Table 3. 2 Antibody cocktails used for MSC phenotyping 
3.2.3 Microscopic analysis of MSC cultures 
In order to gain more insight into the effect of cell size and numbers of the MSC 
cultures on exosome production, MSC cultures where grown to 70% confluency prior 
to the addition of exosome free media. Multiple microscopic images were taken on 
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harvest using GXCapture-T software and ImageJ 1.52i analysis 
(http://imagej.nih.gov/ij) to generate cell number and cell area in µM2 for each MSC 
culture layer across the same magnification  
3.2.4 Collection and extraction of exosomes 
Once stromal culture reached ~80% confluency, growth medium from flask was 
removed, cells were washed using serum free medium and replaced with either 15ml 
if using a T75 or 30ml if using a T175 tissue culture flask of exosome-free medium 
and placed back in the incubator for 5 days.  
Two methods of exosome isolation were used to compare yields: 
1. Commercially available immunoaffinity Exosome Isolation Kit (Miltenyi Biotec, UK)  
2. Gold standard ultracentrifugation technique adapted from Thery et al 2006. 
The isolation of exosomes using the Miltenyi Biotec Exosome Isolation Kit Pan uses 
MicroBeads which recognize the tetraspanin proteins CD9, CD63 and CD81. 2ml of 
exosome conditioned supernatant consecutively centrifuged at 300xg for 10 mins, 
2000xg for 30 mins and 10000xg for 45 mins to remove dead cells and debris. This 
was then incubated with 50µl of MicroBeads at room temperature for 1 hour, during 
which µMACS columns were primed by attaching to the MACS magnetic stand and 
running 100µl of Equilibrium Buffer followed by three washes of 100µl of Isolation 
Buffer. The labelled exosomes were then loaded onto the primed µMACS column 
which was placed within the magnetic field of a µMACS Separator. Magnetically 
labelled exosomes are retained within the column while the unlabelled vesicles and 
cell components run through the column. Exosomes were eluted using 100µl of 
Isolation Buffer and flushed out using a plunger in the column. A summary of the 
protocol is shown in Figure 3.1. 
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Figure 3. 1 Overview of Miltenyi Biotec Exosome Isolation Kit protocol 
The second isolation method used was the ultracentrifugation (UC) technique, 
following incubation, exosome containing medium was removed from flasks and 
combined for centrifugation steps which were carried out at 4°C as outlined in Figure 
3.2. The first two spins at 2000xg for 20 min and 10000xg for 30 min use standard 
centrifugation to remove dead cells and debris, the following spins at 100,000xg for 
70 min use an ultracentrifuge which produces an exosome pellet which is washed 
with PBS and centrifuged, this pellet is resuspended in 25ml PBS and layered over 
4ml of TRIS/Sucrose/D2O solution and centrifuged at 100,000xg for 70 min, the 
sucrose layer was then removed using a 18G needle attached to a 5ml syringe and 
added to 25ml of PBS and a final spin of 100,000xg for 70min produces the purified 
exosome pellet which was resuspended in PBS and stored at -80°C. 
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Figure 3. 2 Summary of exosome isolation using serial ultracentrifugation (adapted from (Li 
et al. 2017)) 
3.2.5 Confirmation of exosome content 
Three methods were used to confirm exosome content according to the guidelines of 
the Society of Extracellular Vesicles (Thery et al. 2018), these included a Bradford 
protein assay to assess protein content, Nanoparticle Tracking Analysis (NTA) to 
assess particle content and western blotting to assess the presence of exosome 
protein markers. 
1. Bradford protein assay 
Method followed as outlined in Chapter 2 apart from the following alterations; 
exosome lysates were prepared by adding 10µl of exosome preparation to 25µl of 
cell lysis buffer. Exosome lysates were diluted 1 in 5 using 5µl and 20µl sterile water 
and aliquoted at 10µl per well in duplicate into 96-well plate before reading in 
spectrophotometer. 
2. Nanoparticle tracking analysis (NTA) 
NTA is a method that visualises and then quantitates nanoparticles (10-1000nM) in 
liquids. This laser-illuminated microscopical technique utilises the properties of light 
scattering and Brownian motion to analyse nanoparticles in real-time. NTA uses high-
intensity laser beams sent through a sample chamber, the particles within suspension 
pass through the beam and cause a scattering of light which can be detected by a 
highly sensitive camera over multiple frames (Figure 3.3). NTA software 3.1 tracks 
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each particle and analyses the velocity of particle movement separately resulting in 
an estimate of particle size and distribution.  
Exosome preparations were diluted using nanoparticle-free water (Fresenius Kabi, 
Runcorn, UK) so that the particle concentration (particles/ml) was within the linear 
range of the instrument (NanoSight NS300), (1:100-1:1000 dilution range). 100nM 
standard latex beads for calibration (Malvern Instruments) were prepared by diluting 
1:1000 using particle free water, mixed and taken up into a 1ml syringe which was 
connected to NanoSight via rubber tubing. Before running exosome samples, tubing 
was washed with particle free water until no particles were detected on the screen. 
Diluted exosome preps were then administered and recorded under controlled flow 
using the NanoSight syringe pump (Malvern Instruments) set at 50μl/min and 
temperatures set at 25°C. Three replicate videos of 1 minute were taken and batch 
analysed using NTA 3.1 software with camera sensitivity and detection threshold set 
at 14-16 and 1-5 respectively using sCMOS Camera System (OrcaFlash 2.8, 
Hamamatsu C11440, Hamamatsu City, Japan), histograms for each triplicate 
measurement were generated and the area under each plot was averaged to be used 
as a particle concentration measurement and corrected for cell number. 
  
Figure 3. 3 Overview of NanoTracking Analysis instrumentation (www.photonics.com) 
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3. Western Blotting 
Exosome lysates were generated and quantitated as outlined previously and western 
blotting was carried out as detailed in Chapter 2. 5-10µg of total protein from exosome 
preps and whole cell lysates were loaded per well and membranes were incubated 
with tetraspanin antibodies CD9, CD81 and CD63 and cytosolic antibody ALIX (Santa 
Cruz Biotechnology, Texas, U.S.A.)  all used at 1:3000 dilution for exosome prep 
validation. Endoglin and CD73 used at 1:5000 dilution (Santa Cruz Biotechnology, 
Texas, U.S.A.) are mesenchymal stem cell stromal markers and GAPDH used at 
1:1000 dilution (Santa Cruz Biotechnology, Texas, U.S.A.)  which is used as a 
cytoplasmic originating marker for exosomes.  
3.2.6 mIR preparation and identification 
To investigate the miRNA content of exosome samples I used two commercially 
available kits to extract miRNA from supernatant collected from MSC cultures 
following five days incubation with exosome-free medium. The two kits are both 
manufactured by Qiagen, miRNeasy Serum/Plasma Advanced Kit (Cat. No. 217204) 
and ExoRNeasy Serum/Plasma Kit (Cat. No. 77044). Protocols were followed 
according to manufacturer’s guidelines and resulting miRNA stored at -80°C.  
To determine the integrity and quantify the miRNA yield from exosome preps I 
compared two methods; the Agilent 2100 Bioanalyzer Eukaryote total RNA 6000 Pico 
Kit (Agilent Technologies, Germany) which uses capillary electrophoresis to separate 
sample components, and detects them by fluorescence which translates into a gel 
like image and electropherogram for analysis. 1µl of miRNA sample was required and 
protocol was followed according to manufacturer’s guidelines.  
The second method used was the Qubit 2.0 Fluorometer (ThermoFisher Scientific, 
UK) which uses fluorescent dyes that upon binding to their target (specific to miRNA 
in this case) become intensely fluorescent, it then uses standards to quantitate. 
miRNA samples were diluted before running on instrument using the Qubit Working 
Solution at 1:200, if a sample was particularly weak the dilution was reduced to 3:200 
dilution, protocol followed according to manufacturer’s guidelines. 
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3.3 Results of exosome identification 
3.3.1 Immunophenotyping 
Exosome preparations were extracted from MSC cultures originating from normal 
bone marrow (NBM, n=7), AML diagnostic (n=10) and post-BMT early (1-2 months, 
n=4), mid (3-6 months, n=7) and late (9 months+, n=4). As outlined in Chapter.2 MSC 
cultures were immunophenotyped at stages of sub-culture to check the differentiation 
status and heterogeneity of stromal formation. When results were combined (Figure 
3.4) there was a uniformity of stromal markers (CD73, CD90, CD105, CD166, CD44, 
CD146) present for MSCs from passage 2 with an associated loss of CD45 and other 
myeloid lineage markers (CD14, CD13, CD33, CD34). 
 
Figure 3. 4 Immunophenotypic flow analysis of primary AML cultures at various stages of 
sub-culture (P0 – P3), (n=32) 
3.3.2 Protein quantification 
The amount of exosome protein preparations per ml of MSC supernatant was 
significantly different between samples of different origin. Normal bone marrow and 
early BMT samples showed the lowest and smallest range of protein concentrations 
compared to diagnostic and mid-late post BMT which showed higher mean protein 
concentration and larger spread of values (Figure 3.5).  
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Figure 3. 5  Protein yield (µg/ml) of exosome preparations originating from MSC cultures of 
normal bone marrow (NBM), diagnostic AML and early (1-2 months), mid (3-6 months) and 
late (+6 months) post-bone marrow transplant (BMT) patients. (**p=0.007). 
3.3.3 Western blotting 
The presence of the transmembrane proteins CD81, CD63 and CD9 and cytosolic 
markers ALIX and GAPDH were used to identify exosomes within ultracentrifugation 
preparations, positive expression of these markers is shown in Figure 3.6 for 
exosome preparations produced from ultracentrifugation of normal (NBM), diagnostic 
(Diag) and post-BMT (BMT) MSC derived cells (A) and within the human stromal cell 
line HS5 (B).  
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Figure 3. 6 Western blot showing the expression of exosome transmembrane markers CD81 
and CD63 and cytosolic exosome markers ALIX and GAPDH within NBM, post-BMT and 
diagnostic derived MSCs (A) and HS5 cell (B) exosome preparations. 
Western blots were run using whole cell lysate and the equivalent exosome 
preparations for HS5 cells and post-BMT AML derived MSCs (Figure 3.7). Within the 
HS5 cells the exosome associated marker CD81 and MSC associated stromal 
markers endoglin and CD73 were present within the exosome preparation but absent 
within the whole cell lysate (A) this was reflected in the post-BMT blot but using CD63 
as the exosome associated marker (B), these results are an important measure of 
the purity of the exosome preparations produced. 
 
 
Figure 3. 7 Western blot comparing the expression of exosome markers (CD81 and CD63) 
and MSC stromal markers (CD73 and Endoglin) between whole cell lysate (WCL) and 
exosome preparations of HS5 cells (A) and post-BMT AML derived MSCs (B). 
3.3.4 NanoSight 
Electropherogram charts produced for each sample analysed by NanoSight provided 
useful information regarding quality of exosome preparation and the spread of EVs 
present. Introduction of the sucrose cushion to the ultracentrifuge protocol was tested 
using exosome preps from HS5 stromal cell lines and the sucrose addition provided 
a better quality of exosome preparation which although less concentrated showed an 
increased uniformity of microparticles <200nm highlighted by a smoother NanoSight 
histogram profile (Figure 3.8 A-B). 
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Figure 3. 8 Electropherograms from NanoSight analysis of HS5 derived exosome preparations 
using ultracentrifuge protocol without sucrose cushion purification step (A) and with (B). 
Samples originating from NBM, diagnostic and post-BMT were analysed and post-
BMT sub-categorised into early (1-2 months) and mid-late (3 months+). Comparison 
of nanoparticles per ml of harvested supernatant showed a significant difference 
between patient subtypes (Figure 3.9A). Mid-late post-BMT samples showed 
significantly higher number and range of nanoparticles (p=0.0066), minimal difference 
was observed between the other patient groups and particle distribution more 
uniform. Quantitation of the exosome preparation purity as dictated by the 
protein:particle ratio (protein concentration and NTA combined) showed a different 
configuration compared to the nanoparticle number assessment (Figure 3.9B). 
Diagnostic samples showed a higher number of protein:particle and a larger range 
compared to all other groups, NBM and mid-late BMT gave the lowest and more 
consistent values.  
Protein:particle ratios were also assessed in serial MSC sub-cultures (Figure 3.9C) 
which was found to be relatively stable. 
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Figure 3. 9 (A) Chart showing NanoSight analysis of MSC derived exosome preparations 
originating from normal bone marrow (NBM), AML diagnostic, early post-BMT (1-2months) 
and mid-late post-BMT (>2months), particles/ml is the number of nanoparticles measured per 
ml of supernatant collected and extracted (**p = 0.0066). (B) Chart showing combination of 
exosome preparation total protein content with nanoparticle measurement as protein: particle 
ratio (pg) as a recognised measure of exosome sample purity (****p = <0.0001). (C) Chart 
showing the effect of sub-culturing MSCs on their exosome production (n=10). 
NanoSight analysis gave the size of each nanoparticle measured within the exosome 
preparations assessed, which allows sub-categorization of particle content for each 
sample into  <100nM, 100-200nM and >200nM. The relative amount of each category 
was then calculated as a proportion of total particles to assess the range of EVs 
present in each sample (Figure 3.10) 
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Figure 3. 10 Chart comparing the presence of nanoparticles within the category <100nM, 100-
200nM and >200nM of exosome preparations derived from patient sub-groups as measured 
by NTA using NanoSight instrument. (*p = <0.0001, n = 28). 
3.3.5 Microscopic Analysis 
Average measurements from multiple fields of view of MSC cultures were combined 
to give a total cell count per field of view and an average cell area calculated from 
each flask. In order to compare samples, I used the size of the flask of origin and 
number of flasks cultured to calculate an average cell number which could then be 
cross-referenced with the exosome production of that MSC culture. Figure 3.11 
shows examples of pictures acquired of MSC cultures from different patient origins. 
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Figure 3. 11 Pictures of MSC cultures from cells of NBM (A), AML diagnostic (B) and AML 
post-BMT origin (C). (Pictures taken with Nikon Microscope 10x magnification and 
GXCapture-T software) 
The number of exosomes released per MSC was significantly different between 
disease stage groups, with post-BMT derived MSCs associated with the highest and 
largest range of exosome numbers (Figure 3.12A). NBM derived MSCs showed the 
lowest exosome numbers. Cell size varied significantly, diagnostic MSCs were 
largest, NBM smallest and post-BMT showed largest range in size (Figure 3.12B). 
70 
 
  
 
 
Figure 3. 12 (A) Chart showing number of exosomes produced per MSC derived from NBM, 
diagnostic and post-BMT AML derived MSC cultures (*p=0.0374, n = 12). (B) Chart showing 
microscopic cell measurement of MSC cultures (*p=0.0151). 
In order to fully characterize the exosome preparations, I combined microscopic 
analysis of cell size and cell number with exosome protein loading and number of 
exosomes produced per cell for corresponding samples. The results showed minimal 
associations, number of cells vs particle loading showed no correlation (Figure 3.13C) 
and cell size showed no impact on exosomes produced per MSC (Figure 3.13A). A 
trend could be observed within the particle loading vs cell size, the highest particle 
loading was produced by cultures containing larger cells originating from diagnostic 
source (Figure 3.13B). 
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Figure 3. 13 Charts showing the association of MSC cell size with exosomes produced per 
cell (A) Amount of protein loaded into each exosome (particle purity) the points in red denote 
diagnostic patients (B) and number of MSCs in culture with exosome particle protein loading 
(C). 
3.4 Results of exosome content 
3.4.1 mIR quantification 
Exosome fractions were assessed for mIR quantity using the Agilent Bioanalyzer to 
analyse miRNA produced by Qiagen miRNeasy and ExoRneasy Kits. Samples were 
run on the Eukaryote total RNA 6000 Pico chip. Total RNA control samples were run 
alongside a group of miRNA preps produced from both kits. Results of the gel image 
show two clear bands for the control RNA (Figure 3.14A), which were absent from all 
other samples as would be expected for cell-free derived mIR sample, these bands 
correspond to ribosomal RNA which in humans 28s has ~5070 nucleotides and 18s 
has 1869 nucleotides and is commonly expressed as a ratio of 28s/18s to indicate 
that purified RNA is intact and hasn’t degraded. The electropherogram showed a 
clearer picture (Figure 3.14B-C), the control total RNA has two clear 18s and 28s 
peaks as expected, this is not the case within the miRNA samples which show the 
highest concentration of RNA below 30bp showing that the RNA being analysed is 
too small to pick up by this instrument and give an accurate measurement.  
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As the Agilent Bioanalyser samples contain high levels of small RNA (Garcia-Elias et 
al. 2017), it lacks the sensitivity needed to accurately quantitate these very small 
molecules from cell-free systems such as exosomes or plasma secretory mIR 
samples and RIN assessments of sample quality are unusable. Therefore Qubit 
analysis was undertaken as a more accurate and sensitive way to quantify miRNA 
samples. 
 
Figure 3. 14 Agilent Bioanalyzer results for miRNA analysis. Gel like image (A) showing control 
RNA and miRNA extracted from miRNeasy and ExoRNeasy kits. Electropherogram 
comparing control total RNA (B) with miRNA originating from HS5 cells (C).    
Following extraction of miRNA and quantitation I compared results from the 
ExoRNeasy Kit (Figure 3.15A) and RNeasy Kit (Figure 3.15B), for both kits the 
diagnostic samples produced the highest yield and greatest variability of miRNA. 
ExoRneasy kit harvested higher concentrations of miRNA for all sample types, this 
agrees with latest research which recommends Qiagen ExoRneasy as the best 
overall kit for better quality miRNA prep as shown by the Qubit analysis, although RIN 
number absent from this measurement as it is not appropriate within a cell free 
sample (Laurent 2018). 
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Figure 3. 15 Charts showing miRNA harvest from MSC cultures of NBM, AML diagnostic and 
post-BMT origin using Qiagen ExoRneasy Kit (A) and Qiagen miRNeasy Kit (B) (*p=0.0424). 
Correlations between miRNA harvested from both Qiagen kits and cell size of the 
associated sample were investigated (Figure 3.16A-B) and a trend for miRNA yield 
to increase with cell size was observed. 
 
 
Figure 3. 16 Charts expressing correlations between exosome cell size and miRNA yield from 
ExoRneasy Kit (A) and RNeasy Kit (B). 
3.5 Discussion 
After comparing two standard protocols for exosome isolation I decided to use the 
ultracentrifugation technique for isolation of exosomes to be used in downstream 
functional and molecular analysis. Ultracentrifugation is the most common method of 
extracting exosomes in published research and is recommended as a relatively easy 
technique with little technical expertise needed and minimal long-term costs and most 
importantly a pure preparation of exosomes. 
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Although ultracentrifugation is a very long and labour intensive technique compared 
to the Miltenyi Biotec Exosome Isolation Kit, it is undoubtedly the superior isolation 
method. The Miltenyi Biotec Kit although quick and easy produced exosomes that 
were irreversibly attached to Microbeads which meant that I was unable to carry out 
quantitative analysis using NTA, as the beads interfered with the laser beam tracking 
device. The beads also interfered with running of electrophoresis gels for 
immunoblotting analysis and could not be used in functional assays, limiting their use 
solely to molecular characterisation. 
The addition of a sucrose cushion purification step within the ultracentrifugation 
protocol added more stages to the technique but results of a comparison of exosome 
preparations produced from HS5 cells (Figure 3.8), clearly showed that this additional 
purification step produces an exosome extract that contained a more uniform type of 
vesicle within the exosome defined limits. A sucrose cushion is not always necessary 
as stated in the Society of Microvesicle Guidelines (Thery et al. 2018) the level of 
purity of your exosome prep should be influenced by your downstream requirements. 
I found that the material lost during the sucrose cushion stages of the protocol is 
substantial, significantly lowering exosome protein yield, this causes problems when 
attempting to run a western blot as it is very difficult to obtain enough exosome protein 
in order to successfully visualise on a nitrocellulose membrane. In the case of western 
blotting, I found that removing the sucrose cushion purification step and lysing the 
exosome pellet directly was more effective when this form of analysis was needed for 
validation of exosome presence rather than content. In the case of functional assays 
the extra purification step is necessary in order to ensure the exosome preparation 
added to cell culture assays is as pure as possible. 
The phenotyping of MSCs as they were sub-cultured showed that past passage 2 
cells had lost their myeloid lineage characteristics and obtained a uniform stromal 
associated phenotype across all samples (Figure 3.5). When looking at the effect of 
early passaging on exosome production no significant change in particle number or 
protein amounts was observed (Figure 3.9C).  
Analysis of the exosome protein and nanoparticle content showed for both there were 
significant differences between the MSC clinical sub-categories (Figure 3.5, 3.9A). 
Samples of diagnostic origin showed highest exosome protein content along with mid-
late BMT, both groups showed large range of values. Nanoparticle Tracking Analysis 
(NTA) showed high particle number and greater spread of values in mid-late BMT. 
Combination of both forms of measurement in the form of protein: particle ratio 
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showed diagnostic samples produce highest number of exosomes and gave largest 
spread of data. Previous studies have shown high numbers of exosome release from 
AML cells compared to normal, confirmed by my findings (Szczepanski et al. 2011) 
but this is the first case of post-transplant assessment in AML.  
It is interesting to observe the exosome production differences between post-BMT, 
mid-late is higher than early BMT and shows similarity to those levels seen in NBM. 
It is not completely unexpected to see similar results for early-BMT and NBM as 
leukaemic burden is reduced/absent after conditioning and donor engrafted cells 
return the marrow to a phenotype similar to that of a normal individual. The increase 
seen in exosome production at later stages of post-transplant could be due to a 
variety of possibilities. Exosomes are important modulators of immune response 
especially in cancer development they can both potentiate an immune response or 
act as an immunosuppressive (Ruivo et al. 2017). Following transplant a patient will 
wean off immunosuppressants and re-build their natural immune defences, this could 
signify an increase in exosome secretion from T-cells which would promote 
development of immune response and help regulate the formation of synapse 
between T-cells and antigen-presenting cells (Barros et al. 2018). Some studies have 
shown a beneficial impact of exosomes on engraftment. An in vivo study involving 
heart allograft MSC derived exosomes were added post-transplant resulting in the 
induction of Tregs and reduction of CD8+ T-cells, reducing allograft immune 
responses and inducing immunotolerance (He et al. 2018).This was also reflected in 
a study involving the addition of exosomes derived from Treg cells which resulted in 
the prolonged survival and function of kidney allografts (Yu et al. 2013).  
In contrast, exosomes could also act in a negative manner within the post-transplant 
environment, as studies have shown that increased exosome quantity released into 
circulation along with their associated cargo could help increase the expression of 
certain proteins which promote T-cell mediated GvHD (Vallabhajosyula et al. 2017) 
,(Fleissner et al. 2012).The increase in diversity of exosome levels in  later stages of 
post-transplant could represent the heterogeneous response to the treatment that 
patients display and may represent immune reconstitution or potentially GvHD and 
GvL response. Further characterisation of patient status and outcome may be 
available for individual samples and will be requested, although much larger cohorts 
of material would be required to confirm this observation. 
Cellular stress is another factor that could bring about an increase in exosome release 
as cells readjust to the changing microenvironment. Previous studies have shown 
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that post-transplant, cell stress can stimulate the release of exosomes from donor 
cells that express mismatched HLA and a lung allograft targeted immune response 
triggered (Ravichandran et al. 2019).    
The other potential implications of increased exosome level observed in mid-late 
transplant samples is the indication of MRD and potential disease resurgence. It has 
already been suggested that exosomes derived from AML could be used to detect 
MRD although this has not yet been put into practice, as confirmation of this process 
is currently constrained  by lack of  reliable techniques for isolation of exosomes from 
different origin (Boyiadzis M 2016). 
Exosomes isolated from breast cancer patients were shown to express the marker 
protein CD24 but not EpCAM protein, this differed from those exosomes isolated from 
normal exosomes that expressed both and so could be used as a biomarker for 
prognosis or diagnosis (Rupp et al. 2011). It has also been determined that EDIL3 
and fibronectin are present on extracellular vesicles of breast cancer patients and 
levels reduced in concordance with surgical treatment enabling them to be used as 
indicators of therapeutic response (Moon et al. 2016a; Moon et al. 2016b). 
NTA analysis using NanoSight measures the size of all particles for each sample 
analysed which enabled me to sub-categorise each sample into % composition of the 
following groups; <200nM (small microvesicles), 100-200nM (exosomes) and 
>200nM (large microvesicles) (Figure 3.10). Between categories for all samples there 
were significantly more particles of size 100-200nM, confirming that all sample 
preparations were composed of exosomes in the highest quantity. There was no 
significant difference seen between the clinical groupings although once again the 
largest range in particle size within the 100-200nM group was within the diagnostic 
samples, this agrees with all previous observations and the large spread of data 
perhaps is linked to the characteristic heterogeneity of AML. 
Microscopic analysis of MSC cultures highlighted a significant difference between 
clinical categories when comparing number of exosomes produced per cell as 
calculated using microscope cell counts and NTA (Figure 3.12A). Cells producing the 
lowest number of exosomes originated from NBM as expected (Hong et al. 2014a) 
and diagnostic and post-BMT showed higher exosome number and spread of data. 
Cell size analysis (Figure 3.12B) showed that the smallest cells were observed from 
NBM, diagnostic cultures contained the largest cells and a range of cell sizes were 
seen in post-BMT cultures. This observation agrees with previous work that showed 
an overall increase in cancer cell size compared to normal. The heterogeneity of the 
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post-transplant cell size could reflect the different stages of bone marrow recovery 
experienced within this cohort of patients (Shashni et al. 2018). 
miRNA was extracted using miRNeasy and ExoRNeasy Kits. Agilent Bioanalyzer was 
initially used to quantitate the miRNA but was rejected due to problems quantifying 
small RNA, giving inaccurate measurements of miRNA concentration. I successfully 
quantitated using Qubit Instrument which due to it’s increased sensitivity could 
accurately measure miRNA levels in all samples. ExoRneasy produced higher yield 
of miRNA from the same samples as RNeasy and as other studies have also 
concluded, is the best choice (Garcia-Elias et al. 2017).  
miRNA produced from both kits produced a higher yield from diagnostic samples 
(Figure 3.15A-B) suggesting an association between high levels of miRNA and 
increased numbers of exosomes in these samples. Previous work agrees with this 
and has shown that amount and composition of exosomal miRNA differs between 
patients with disease and healthy individuals (Zhang et al. 2015).  
In summary: 
-  Ultracentrifugation best choice for exosome isolation only use sucrose 
cushion purification step if carrying out functional downstream applications 
- ExoRNeasy Kit is best for miRNA extraction and Qubit instrument most 
sensitive quantitation.  
- Diagnostic samples show highest exosome production and miRNA content 
which agrees with previously published work 
- No correlation found with MSC size and exosome production, but rather 
production activity is related to disease stage. 
- Increased miRNA yield shows some association with higher exosome 
production as seen in diagnostic samples 
- Early-BMT exosome production shows a stabilization of exosome production 
similar to that of NBM. 
- Mid-late BMT exosome production shows a much larger spread of responses 
in which some retain NBM like levels and others return towards their 
diagnostic levels which could be in response to cell stress or potential indicator 
of MRD/relapse. 
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4 Chapter 4: Validation and Functional Exosome Assays 
4.1 Introduction 
4.1.1 Exosome function within the bone marrow microenvironment 
Many studies have investigated the function of cancer cell derived exosomes and 
exosome interaction within the tumour microenvironment is a growing field exploring 
the major role in intercellular communication between cell types helping to support 
tumour growth, differentiation, proliferation, angiogenesis, immune evasion and drug 
resistance. 
It has been reported that exosomes help block cell differentiation and modulate target 
cells via miRNA transfer. Previous work has shown that exosomes originating from 
endothelial and haematopoietic cells disrupt Notch signalling through miR126 transfer 
resulting in an increase of cell differentiation (Liao et al. 2018). Exosomes derived 
from other cell types including neuronal progenitor cells and macrophages, have also 
been shown to promote differentiation usually from naïve to mature cell type. This 
process is not restricted to healthy cells, exosomes released from malignant cells 
have been shown to block their own differentiation and inhibit the differentiation of 
non-supportive cells (Yu et al. 2007). 
Exosomes within the malignant microenvironment serve as good candidates for 
biomarkers of disease. They contain genetic and proteomic contents that can reflect 
the cell of origin and protect their cargo from potential degradation from nucleases 
and proteases. This increases the biomarker half-life and protects the sample integrity 
for successful downstream analysis. This has successfully been used to monitor 
disease in a wide variety of cancers such as lung, breast and colon(Corcoran et al. 
2011; Cazzoli et al. 2013; Ogata-Kawata et al. 2014). Studies in AML have shown 
that exosome levels present in patient plasma reflect disease load, and after a course 
of induction chemotherapy levels of exosome protein significantly reduce concomitant 
with that of leukaemic blasts in the bone marrow. Other work has highlighted the 
presence of TGF-β1 levels in exosomes derived from AML patients following 
chemotherapy, where exosomal TGF-β1 levels were significantly reduced in patients 
with long-term complete remission, suggesting that changes in exosome derived 
TGF-β1 levels may reflect therapeutic response (Hong et al. 2014b).  
Exosomes have been shown to modulate angiogenesis by stimulation or inhibition, 
these effects are dependent on exosome content and surface molecule expression 
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factors, which are normally under the direction of the stimulus which induces exosome 
release. Mechanisms involved in the stimulation of exosome angiogenesis include 
the transfer of mIRs e.g. MIR-126, proteins e.g. CKIT and lipids e.g. S1P90 along with 
activation of various signalling pathways. One of the most common being ERK1/2 
and the transfer of transcription factors. Exosome directed inhibition of angiogenesis, 
is known to take place through the mechanisms of LDL receptor mediated 
endocytosis and induction of oxidative stress. 
Pancreatic cancer exosomes have been shown to induce the fibrotic migration 
inhibitory factor and TGFβ leading to microenvironment remodelling creating 
favourable conditions for liver metastasis (Costa-Silva et al. 2015). Studies have 
shown another factor which further enhances the role of exosomes in pre-metastatic 
niche formation is the presence of PD-L1 on their cell surface. A study on metastatic 
melanoma showed that when this binds to PD-1 found on macrophages, T and B-
cells, it creates an immunosuppressed microenvironment which increases disease 
progression (Chen et al. 2018). 
Studies have investigated the function of cancer derived exosomes and immune 
response. MHC+ exosomes from both tumour and immune cells have been shown to 
bring about a T-cell specific immune response (Andre et al. 2002). In contrast other 
studies have reported the opposite effect of exosomes, within a malignant 
environment aiding immune surveillance evasion and activating macrophage 
inflammatory responses (Abusamra et al. 2005; Yu et al. 2007). 
Studies on leukaemia derived exosomes have shown that exosomes released from 
leukaemic cells alter their proliferative and migratory response. AML derived 
exosomes have been shown to transfer mRNA to surrounding bone marrow stromal 
cells, a study involving human derived exosomes enriched with CXCR4 and IGF-IR 
transcripts were co-cultured with murine bone marrow stromal target cells and 
showed the factors were present in the recipient cells, confirming the functional 
consequences of AML exosome trafficking (Huan et al. 2013). Within the bone 
marrow microenvironment, CML derived exosomes were shown to stimulate the 
release of IL8 from the surrounding stromal cells, helping to promote disease survival 
(Corrado et al. 2014). Studies have also shown that CML derived exosomes transfer 
mIR-126 directly to endothelial cells, targeting CXCL12 and VCAM1 mRNA 
increasing the adhesive and migratory capacity of the CML cells (Taverna et al 
(Taverna et al. 2014).  
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Studies involving multiple myeloma (MM) derived exosomes showed that when co-
cultured with MM cells  a transfer of mIR-15a took place from MM-derived exosomes 
which resulted in increased MM cell proliferation and survival. This was absent from 
normal bone marrow-MSC derived exosomes which instead showed growth inhibition 
of MM cells (Roccaro et al. 2013). 
An undesirable function of exosomes within the therapeutic environment is their ability 
to horizontally transfer drug resistance, as seen in a study using MM cells co-cultured 
with bone marrow stromal cell derived exosomes, as well as increasing proliferation 
of the MM cells they also induced drug resistance to Botezomib (Wang et al. 2014), 
studies suggest that this is thought to be due to the intercellular transfer of miRNA by 
exosomes from drug-resistant to sensitive cancer cells (Litwinska et al. 2019).  
Several studies have investigated the potential benefits of using combinations of 
novel drugs to overcome AML chemo-resistance, but when combination therapies are 
tested in stromal co-culture a much higher therapeutic dose is required suggesting 
stromal niche contributes to resistance (Weisberg et al. 2008). Further co-culture 
studies using primitive leukaemic populations showed that as well as displaying drug 
resistance these cells are non-cycling and retain their leukaemic genetic mutations 
such as FLT3-ITD (Alvares et al. 2011; Parmar et al. 2011). 
This highlights the important function exosomes play in providing a form of 
communication between cancer and host, aiding disease progression.  
4.1.2 miRNA profiling in exosomes 
miRNA can be transported as cargo within exosomes, or extracellular miRNA can be 
loaded onto high density lipoproteins or bound by Argonaute2 protein on the outside 
of the exosome. miRNA cargo is thought to be well protected via all modes of 
exosome transport (Arroyo et al. 2011; Tabet et al. 2014).  
Once exosome miRNA is delivered to the recipient cell it plays a functional role, which 
consists of typical negative regulation that confers changes in expression levels of 
specific target genes involved in many biological processes such as apoptosis, 
proliferation, and immune response. Recently, novel functions of exosome mediated 
mIR transfer have been identified, where exosome miRNA acts as a ligand binding to 
toll-like receptors and activating immune cells (Fabbri et al. 2012). 
Large scale microarray studies of primary cells and cell lines originating from 
melanoma, breast and ovarian cancer, show a high frequency of genomic alterations 
within miRNA loci, suggesting that the abnormal miRNA expression in malignant cells 
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could arise from amplification or deletion of specific genomic regions containing 
miRNA genes (Zhang et al. 2006). 
Studies have shown that miRNA is also susceptible to epigenetic modulation. In AML 
mIR-223 expression was epigenetically silenced by the AML1/ATO fusion protein 
through CpG methylation (Fazi et al. 2007). 
4.1.3 Stromal support in AML  
As previously summarized, MSCs of the bone marrow microenvironment have been 
recognised as playing a major role in leukaemic progression, supporting AML growth 
and mediating chemoresistance. It has been shown in vitro that co-culture with AML 
patient stromal cells, drives resistance to Ara-C in some patient samples and these 
patients are associated with a poor clinical outcome. This resistance is mediated by 
both direct cell to cell contact and also the soluble secretory molecules released from 
the bone marrow stromal cells, that protect AML cells from Ara-C induced cytotoxicity 
(Macanas-Pirard P 2017   ).  
The effect of exosome release from both AML and stromal cells have previously been 
found to incite leukaemic behaviour, in the form of increased cell proliferation, immune 
evasion and drug resistance. In one study, normal and AML derived stromal 
exosomes conferred a resistance to Ara-C drug treatment, however only AML-derived 
exosomes inhibited the efficacy of the drug AC220, suggesting a differential 
therapeutic response between NBM and AML stromal cells (Viola et al. 2016). 
A recent study used reverse protein array technology to look at key proteins involved 
in a number of signalling pathways associated with stroma-mediated AML survival 
within both primary and cell line AMLs, and showed that the stroma reprogrammed a 
number of signalling networks, including PI3K/AKT/MTOR and BCL2 which modified 
the sensitivity to several targeted agents (Zeng et al. 2017).  
Similarly, profiling of exosomal protein content is a relatively new field of research, 
and a recent study of plasma exosomes in epithelial ovarian cancer identified 294 
proteins within both cancerous and non-cancerous samples, the results of which 
could be used for diagnostic and prognostic purposes (Zhang et al. 2019). It has also 
been suggested that MSC derived exosomes work through a protein based 
mechanism of action and that proteins could be the main driver of therapeutic action 
as opposed to miRNA which is found at significantly lower levels compared to protein 
in exosomes (Toh et al. 2018).  
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Given the clear evidence of stromal protection and modifying effects on AML blasts 
during chemoresistance and residual disease, further characterisation of exosome 
mediated signalling pathways, and functional phenotypes involved is required to 
assess their contribution to stromal support. 
4.2 Methods 
4.2.1 Luminex Assay 
In order to investigate the content of primary AML MSC derived exosome and 
matched supernatant samples I used a Luminex Assay as a way of profiling disease 
specific biomarkers. Luminex is a multiplex immunoassay which can simultaneously 
detect and quantify multiple target analytes within complex sample types and only 
requires small volumes of sample, an overview of the technique is shown in Figure 
4.1.  
 
Figure 4. 1 Summary of Luminex assay principle (www.rndsystems.com) 
Exosome preparations were lysed using a cell extraction buffer as outlined in 
Chapter.2. The lysis buffer is important as it needs to contain enough detergent to 
solubilise the proteins within the sample but avoid such high concentrations that will 
interfere with assay sensitivity, for example using buffers containing ionic detergents 
such as traditionally used RIPA buffer. The buffer we chose to use contained low 
levels of ionic detergent SDS which we diluted 1:10 before running to ensure correct 
final concentration and no downstream interference. 
Custom made Human Premixed Multi-Analyte Kits for luminex analysis (R&D 
Systems Inc, Minneapolis, U.S.A) were designed to encompass a panel of 104 
cytokine/survival targets detailed in Table 4.1. 
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Table 4. 1 Luminex multiplex panel targets  
Luminex Assay was run as outlined in Chapter.2.  
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4.2.2 Taqman Multiplex Assay 
miRNA was extracted using Qiagen ExoRNeasy Kit as previously described and 
samples were diluted accordingly using sterile water and used at a concentration of 
1µg of miRNA per reaction. TaqMan Advanced miRNA and cDNA Synthesis Assay 
Kits (ThermoFisher Scientific, Massachusetts, U.S.A) were used and manufacturers 
protocols followed to carry out poly(A) tailing, adaptor ligation, reverse transcriptase 
and mIR-Amp reactions. All reactions were run on GeneAmp PCR System 9700 
V.3.10 (Applied Biosystems Ltd.). The mIR-Amp reaction product was diluted 1:10 
with 0.1X TE buffer (Fisher Scientific UK Ltd) and 5µl used per reaction using 
TaqMan Advanced miRNA Assay Kit for targets mIR155, mIR1246 and 
housekeeping control mIR361. Reactions were set up in MicroAmp Optical 96-well 
plates (Applied Biosystems Ltd.) in triplicate including a water blank and positive 
control and run on QuantStudio 5 System (ThermoFisher Scientific, Massachusetts, 
U.S.A.) using fast cycling mode and programme as manufacturer’s instructions. 
Data was analysed using software package QuantStudio Design and Analysis 
Desktop Software Version 1.4.3 which generated Ct values for each sample which I 
then used to calculate 2ΔΔCt to assess relative expression levels for each target.  
4.2.3 Tissue Culture Functional Assays 
4.2.3.1 Cell Proliferation Assay 
HS5 cells were maintained and seeded onto 48-well tissue culture plates in advance 
as described in Chapter 2. MV411, KG-1a, HS5 and primary AML cells were cultured 
(as described in Chapter 2) and seeded +/- HS5 stromal layer as required at 7.5x105 
cells/ml primary AML cells and 1x105 cells/ml cell lines. Exosome preparations 
(generated through sucrose cushion density gradient) were made up to the required 
concentration using sterile 1XPBS before adding directly to culture and placing into 
37°C incubator for 48 hours. Following incubation supernatant was removed and cells 
pelleted for flow cytometry as outlined in Chapter.2. In order to assess cell viability 
and suspension vs adherent fractions flow cytometry was carried out using CD45 to 
identify stromal and myeloid cell populations. 
4.2.3.2 Migration Assay 
HS5 cells were seeded into 24 well chemotaxis tissue culture plate (Corning Costar 
#3421) as described in Chapter.2. 24 hours before start of assay plate inserts were 
rinsed with sterile 1x PBS and pre-warmed medium added to receiver wells.100μl of 
chemotaxis medium was added to inserts and transferred to a well containing medium 
+/-HS5. KG-1a cells were counted and 100μl added at 2x105/ml into the plate inserts. 
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Exosome preparations were isolated by sucrose density gradient and made up in 
sterile 1XPBS to add at 200μg per receiver well. Inserts containing cells were added 
back into plate and incubated for 24 hours. To harvest, the inserts were removed and 
contents transferred to centrifuge tube, insert was rinsed with 250μl of medium and 
combined, this procedure was repeated with the wells and HS5 stromal layers 
trypsinised and harvested as described in Chapter 2. All cell extracts were centrifuged 
at 1200rpm and flow cytometry carried out as described in Chapter.2 with CD45 and 
7AAD for cell viability assessment. 
4.2.3.3 Cell Glo drug cytotoxicity assay 
Pacritinib (molecular weight 472.58) was supplied by CTI Biopharma Corporation 
(Seattle, WA, U.S.A) in 0.5% methylcellulose (w/v) and 0.1% Tween-80 in H2O, made 
up to working stock concentration of 10mM by dissolving in DMSO and diluted in 
IMDM media to a top dose of 100 µM. 50μl of IMDM was placed in each well of an 
opaque walled 96-well plate, excluding the outside wells where evaporation is more 
likely to occur. Top dose wells were made up to 100ul with further medium and drug 
added from the top dose Pacritinib to give a 2x of final concentration. Serial dilution 
using 50µl from the top wells was applied across the 96 well plate resulting in 10 
doses in triplicate. Control wells were set up using DMSO at equivalent 
concentrations to that found in the top dose wells. Finally, 50μl of primary AML cells 
+/- exosomes diluted in IMDM from 5 x 106/ml suspension were added to all the drug 
and DMSO wells (8x104/well) and then plates were incubated at 37°C, 5% CO2 for 
48 hours. Cell Titer Glo (Promega) assay was performed to determine the number of 
viable cells that remained; this is a luminescent viability-based assay where the 
number of viable cells in a culture can be determined based on their ATP content, 
which signals the presence of metabolically active cells. At the end of 48 hours, Cell 
Glo reagent was defrosted at room temperature and shielded from light. Plates were 
removed from the incubator and allowed to equilibrate to room temperature for 1 hour 
(to prevent temperature gradients which may affect the rate of the luciferase reaction), 
then 100μl Cell Glo was added to each well and the plates were then shaken 
protected from light on an orbital shaker for 2 minutes to allow complete lysis of cells. 
Plates were read using a Chameleon automated plate reader (Hidex, Finland) on 
single direct luminescence setting with the aperture adjusted for RLU in the range of 
20,000 – 5,000,000. The amount of ATP and therefore the luminescence reading is 
directly proportional to the number of live cells present in culture within this range. 
Dose response curves were established for cell viability as a percentage of the 
untreated/DMSO control and software package Calcusyn version 2.1 (Biosoft, 
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Cambridge. UK) was used to calculate a 50% inhibitory concentration (EC50) for 
cytotoxic responses to Pacritinib +/- exosomes based on the luminescence data. 
4.2.3.4 Western blotting – ERK  
KG1a cells were cultured +/- HS5 cells as previously described in triplicate T75 tissue 
culture flasks and exosome free medium added overnight to HS5 cells. Medium was 
removed the following day and replaced with KG1a cells in exosome free medium at 
2x105cells/ml. MEK-PD (Sigma-Aldrich PZ0162) resuspended in DMSO was added 
to relevant flasks at 10μM and 100μM and DMSO alone added to control flasks for 
48 hours.  Exosome supernatants were removed and centrifuged at 1200rpm prior to 
exosome extraction and protein lysis carried out as described in Chapter.2. KG1a cell 
pellets were lysed for western blot analysis as previously described. Western blotting 
was carried out as previously described in Chapter 2 and  the following antibodies 
were used to probe: ERK (Cell Signalling 4370) at 1:5000 dilution, CD81 (Santa Cruz 
SC-166029) at 1:1000 dilution and GAPDH (Santa Cruz SC-47724) at 1:5000 dilution. 
Rabbit secondary antibody was used at 1:25000 dilution. 
4.2.3.5 Western blotting – Luminex Validation 
Western blotting was carried out as previously described in Chapter.2 using exosome 
lysates and probed using Her/erbb3, ICAM-1, GAPDH and CD81 at dilutions as 
described in Table 2.1. 
4.3 Results 
4.3.1 Luminex Target Identification 
Supernatants and matching exosome preparations derived from MSC cultures of 
normal, AML diagnostic, early post-BMT and mid-late post-BMT origin were collected 
and as described previously prepared for luminex anlysis. Samples were analysed on 
a custom panel of 104 targets and following analysis were quality checked  to remove 
any failed targets or samples. 
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Figure 4. 2 Chart comparing average detection levels of cytokine targets as analysed by 
Luminex comparing NBM to AML samples (A) and exosome to supernatant samples (B) 
(n=18). 
Targets were ranked in order of abundance and normalised to total protein load. AML 
derived stromal exosomes contained higher levels of targets overall compared to 
NBM derived stromal exosomes (Figure 4.2A). When compared to matched 
supernatant secretory profiles, exosome profiles contained fewer detectable targets 
than the parental secretory supernatant although some targets showed equivalent 
levels of abundance to that of the supernatant (Figure 4.2B). 
To look at the distribution of data profiles Partek Genomics Suite 5 was used to 
identify clustering patterns. Figure 4.3 shows a hierarchichal cluster chart for 
exosome (A) and supernatant (B) samples. Exosome samples show a clear division 
between high overall expression of targets in NBM and diagnostic samples compared 
to post-BMT samples. Further investigation into these clusters identified Leptin, 
osteopontin, LIF, C-kit, insulin, BMP4, ccl22, TIMP-1 and serpin-e1 as the targets 
more highly expressed in NBM and diagnostic compared to post-BMT samples which 
showed low expression.  
Supernatant samples showed a trend for NBM and diagnostic separating out into 
clusters. Diagnostic samples showed higher levels of ICAM-1, LIF, MIF, CXCL9, 
BAFF, APRIL, CXCL1, EphA2 and Fas ligand. In NBM higher levels of MMP-3, CCL5, 
IL-1RA and CEACAM-1. 
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Figure 4. 3 Hierarchichal clustering analysis of NBM, diagnostic AML, early AML post-BMT 
and mid-late BMT MSC derived fractions of exosome (n=20) (A) and supernatnant (n=37) (B)  
Prinicpal component analysis (PCA) is a statistical method which uses an algorithm 
to convert a set of variables which could be correlated, into a set of values that are 
linearly uncorrelated, it then attempts to explain the maximum amount of variance 
with the fewest number of principal components. A chart showing a representation of 
PCA analysis of exosome sample luminex content (Figure.4.4A) shows disctinct 
clustering of each disease stage with NBM samples show the largest spread of data, 
and post-BMT showing least variability. Early and mid-late BMT samples showed the 
most similar common profiles and diagnostic samples show the least amount of 
correlation to post-BMT samples. 
PCA analysis of supernatant samples (Figure.4.4B) show the largest spread of data  
within the diagnostic samples, early post-BMT show the least amount of data 
variability and NBM and mid-late BMT show most correlation to each other.  
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Figure 4. 4 PCA (principal component analysis) of NBM, diagnostic AML, early AML post-BMT 
and mid-late BMT MSC derived fractions of exosome (n=20) (A) and supernatnant (n=37) (B)  
In order to further investigate target differences between patient groups and cytokine 
expression, exosome luminex targets were sub-categorised according to their 
function; immunology, survival/differentiation, adhesion and chemoattract and their 
overall abundance plotted for each sample group (Figure 4.5). VCAM-1 was the target 
most highly expressed within all sample types. ICAM-1 was also expressed highly 
within NBM, diagnostic and mid-late BMT. IL-4 and IL-10 were most highly expressed 
in early BMT and IGFBP-3 in mid-late post-BMT. 
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Figure 4. 5 Summary of Luminex target abundance levels from exosome samples derived 
from NBM (A), Diagnostic (B), early post-BMT (C) and mid-late post-BMT (D). Targets are 
categorised according to function; adhesion, immunology, chemoattract and 
survival/differentiation (n = 20). 
Results show that there are differences between patient sub-sets and target 
abundance levels between exosome and supernatant samples. The pie charts in 
Figure 4.6 summarise the sample type and levels of expression of particular functional 
targets present within exosome and supernatant samples to try to identify more 
clearly potential changes. It is clear that NBM and diagnostic samples differ 
considerably between exosome and supernatant but become more similar within 
post-BMT. Both sets of sample show a big change in sample makeup post-transplant, 
exosome samples show highest levels of adhesion related targets, this changes early 
post-BMT to a predominatly immunological profile and then survival/differentiation 
late post-BMT. 
Supernatant fractions show profiles at NBM and diagnostic which are heavily 
survival/differentiation biased, this changes early post-BMT to a predominantly 
immunology based profile as seen in exosomes and mid-late post BMT the profile 
reverts back to survival/differentiation. 
In summary, within both exosome and supernatant NBM and diagnostic show similar 
content, this changes post-BMT exosome content differing to supernatant but both 
showing a change with time. This is useful information as it highlights the importance 
of serial timepoint sampling in order to achieve accurate monitoring of disease 
progression. 
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Figure 4. 6 Pie Chart showing proportional representation of targets associated with adhesion, 
survival/differentiation, immunology and chemoattract present within exosome (A) and 
supernatant (B) samples derived from MSC cultures of NBM, AML diagnostic and AML post-
BMT (n = 20). 
In order to further explore the highlighted differences seen between patient treatment 
stage for individual targets I plotted them individually for exosome and the 
accompanying supernatant abundance levels for comparison in order to identify 
similar trends of target abundance between the two sample types (Figure 4.7-4.10).  
Within the immunology panel of exosome samples (Figure 4.7) a trend of increasing 
target expression levels from NBM and diagnostic through to post-BMT was observed 
although this was only significant for Erbb2 (p=0.0404). This trend was not reflected 
within the supernatant samples. 
 
 
Figure 4. 7 Chart showing levels of immunology targets in normal, AML diagnostic and AML 
post-BMT MSC derived exosome (n=20) and supernatant (n=37)  fractions as measured by 
Luminex immunoassay (* p=0.0404). 
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Survival/differentiation targets (Figure 4.8A-B) of exosome preps showed consistently 
lower levels within post-BMT samples for all targets except IGFBP-3 and showed a 
significant difference of; HGF (p=0.0357), BMP-4 (p=0.0286), protein-S (p=0.0159) 
and c-kit (p=0.0159). LIF also showed a significantly higher level of expression in 
diagnostic compared to NBM (p=0.0485). 
This pattern of expression was not repeated in the supernatant fractions, only IGFBP-
3 showed significantly lower levels of expression in post-BMT (p=0.0120), expression 
levels were elevated in diagnostic samples but not to a significant extent, in general 
the greatest variation was seen in the supernatant compared to the exosome 
samples. 
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Figure 4. 8A-B Chart showing levels of survival/differentiation targets in normal, AML 
diagnostic and AML post-BMT MSC derived exosome (n=20) and supernatant (n=37)  
fractions as measured by Luminex immunoassay.  *p= <0.05 
Adhesion related targets (Figure 4.9) show higher levels of expression for NBM 
samples for VCAM-1 and significantly MCAM (p = 0.0357) in exosome fractions which 
is lost in post-BMT samples. Supernatants also show higher levels of expression for 
these targets and significantly for MCAM (p = 0.0349) within the diagnostic samples.   
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Figure 4. 9 Chart showing levels of adhesion targets in normal, AML diagnostic and AML post-
BMT MSC derived exosome (n=20) and supernatant (n=37)  fractions as measured by 
Luminex immunoassay.  *p = <0.05  
Chemoattract targets in exosomes don’t show any significant difference between any 
of the patient sub-categorys for exosomes but they do show a trend towards higher 
levels within post-BMT samples for CCL2 and CCL4. This trend is reflected in the 
supernatant fraction for CCL22 which is significantly more highly expressed in post-
BMT (n=0.0238 ). In CCL2 and CCL4 the levels of expression are highest within the 
diagnostic samples but this is not significant. 
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Figure 4. 10 Chart showing levels of chemoattract targets in normal, AML diagnostic and AML 
post-BMT MSC derived exosome (n=20) and supernatant (n=37)  fractions as measured by 
Luminex immunoassay.  *p = <0.05  
4.3.2 Luminex Validation Assays 
To confirm target expression identified by Luminex analysis I carried out western 
blotting and ELISA assays using target antibodies in order to validate some of the 
luminex results. 
Exosome extractions derived from MSC cultures of normal (NBM), diagnostic AML 
(Diag) and post-BMT AML (BMT) origin were run on a western blot as outlined in 
Chaper.2 and probed for CD8 to confirm exosome status and two targets Her/erbb2 
and ICAM-1 (Santa Cruz Biotech.,U.S.A) (Figure 4.11). Both targets showed an 
upregulation in post-BMT samples compared to an absence in normal, this was also 
observed within the  diagnostic fraction for ICAM-1, these results reflect those seen 
within the Luminex analysis.  
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Figure 4. 11 Western blot showing MSC derived exosome preparations from primary  normal 
bone barrow (NBM), AML diagnostic (Diag) and post-BMT (BMT) probed for exosome 
tetraspanin control (CD81), ICAM-1 and Her/erbb2.  
MSC derived exosome extractions from leukaemic cell lines KG1a and Molm14 and 
all patient categories were used to carry out a permeabilized ELISA assay as outlined 
in Chapter.2 using antibodies ALIX, TIMP-1 and IGFBP3 as detailed in Table 2.1 at 
a concentration of 1μg/ml. The presence of ALIX was probed first as a control target 
for exosomes (Figure 4.12A) and showed similar levels in both primary and leukaemic 
cell lines as expected. An increased level of TIMP-1 was observed within the post-
BMT samples compared to diagnostic and normal bone marrow which was significant 
(p=0.0109), and reflected those seen in the Luminex analysis (Figure 4.12B). A trend 
for higher levels of IGFBP3 could also be identified in the post-BMT also reflected in 
the Luminex results although this was not significant (Figure 4.12C).  
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Figure 4. 12 Charts showing the results of permeabilized ELISA assays using MSC derived 
exosome preparations from primary AML and leukaemia cell lines (KG1a and Molm14) using 
exosome control target ALIX (A) and  normal bone marrow (NBM), AML diagnostic and post-
BMT for targets TIMP-1 (B) and IGFBP3 (C) (n=3) (*p = 0.0109). 
4.3.3 TaqMan Assay 
To assess the expression of two target mIRs commonly dysregulated in leukaemia, I 
carried out Real-Time PCR using a method as outlined in 4.2.2. Primer sets for 
mIR155 and mIR1246 were used and miRNA harvested from MSC derived exosomes 
samples from NBM, diagnostic and post-BMT analysed in order to compare target 
expression. For target mIR 1246 (Figure 4.13A) results showed a significant increase 
in expression of diagnostic (p = 0.0238) and post-BMT (p = 0.0357) compared to 
NBM. Expression of mIR155 (Figure 4.13B) also showed a trend of higher expression 
in diagnostic and post-BMT compared to NBM but this was not significant. Both 
targets showed high levels of variability within the post-BMT samples.  
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Figure 4. 13 Charts show the TaqMan RT PCR analysis of mIR1246 (A) and mIR155 (B) 
expression within MSC derived exosomal miRNA of Normal (NBM), AML diagnostic and post-
BMT samples (n = 15), (*p = <0.05). 
4.3.4 Functional Assays 
To assess the functional behaviour of exosomes within co-culture, assays using the 
FLT3-ITD mutant leukaemic cell line MV-411 and exosomes derived from HS5 
stromal cultures were set up adding 0-20 μg/ml of exosome preparations as outlined 
previously for 48h. Flow cytometry was used to assess cell viability and a dose 
dependent significant increase was observed upon addition of exosomes when co-
cultured with HS5 stromal cells (p=0.0032) and HS5 cells alone (p=0.0007), no 
increase in cell number was seen when MV4-11 cells were cultured alone, (Figure 
4.14A-C).  
To check exosomal effect in another cell line I used the leukaemic p53 mutant cell 
line KG-1a increasing concentrations of exosome preps derived from HS5 stroma, 
diagnostic AML-MSC and NBM-MSC (0-60μg) Figure 4.14D-E. When KG-1a cells 
were cultured without stromal support (D) a small increase in cell proliferation was 
observed for all exosome additions although not significant, this was reflected in the 
presence of stroma (E). A dose dependent increase in cell proliferation was seen on 
HS5 cells alone with all exosome preparations used (F) (*p = 0.0120). 
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Figure 4. 14 MV411 cells were cultured +/- HS5 stromal cells over 48h with addition of 0 - 
20μg of HS5 derived exosomes and proliferative effect assessed using flow cytometry of 
MV411 alone (A) *p=0.0002, co-culture with HS5 cells (B) *p=0.0032, HS5 cells alone (C) * 
p=0.0007 (n=3). KG1a cells were cultured over 48h +/- HS5 stromal cells with addition of 0 - 
60μg of HS5, AML diagnostic and NBM derived exosomes and proliferative effect show on 
KG1a alone (D), co-culture with HS5 cells (E) and HS5 cells alone *p = 0.0120 (F) (n=3). 
Although the effects of exosomes on KG1a cells were small, I investigated the 
potential effects on different sub-populations of cells in order to determine if the 
phenotype was more pronounced. Co-culture assays were harvested into adherent 
and suspension KG1a fractions and analysed by flow cytometry using CD45 antibody 
and viability staining as detailed in Chapter.2 (Figure 4.15). Results showed that upon 
addition of HS5 derived exosomes a small increase in cell proliferation was observed 
for both adherent and suspension fractions. When diagnostic and NBM derived 
exosomes were added there was no increase in cell proliferation within the 
suspension fraction, but a prominent increase within the adherent fraction was 
observed which was significantly higher within the diagnostic fraction (p = 0.0313) 
and an overall significant increase was observed following addition of exosome 
irrespective of origin (p = 0.0006). NBM derived exosomes showed an increased 
boost to cell proliferation in adherent cells compared to HS5, and diagnostic derived 
exosomes and concurrently suspension cell number was reduced, differences 
between suspension and adherent fractions were significantly different within the 
NBM exosome sub-set (p = 0.0286). 
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Figure 4. 15 KG1a cells were co-cultured +/- HS5 cells with HS5, AML diagnostic and NBM 
derived exosome at 0-60μg. Adherent and suspension fractions were separated post 48h 
incubation and proliferative effect assessed using flow cytometry (n=3) *p = 0.03. 
Given the effects observed on KG1a adhesion I investigated the effects of exosomes 
on the migratory behaviour of KG-1a cells using a chemotaxis tissue culture plate as 
outlined previously. Total cell counts collected at the end of the assay showed no 
overall additional enhancement on KG-1a cells with addition of exosomes when 
cultured alone, but when in presence of stroma growth is further enhanced (Figure 
4.16A). When cultured alone KG-1a cells showed limited migration and presence of 
exosomes did not have any additional effect (Figure 4.16B). When KG-1a cells were 
cultured in the presence of stroma they migrated towards the HS5 cells but again the 
addition of exosomes had no significant impact (Figure 4.16B).  
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Figure 4. 16 Chart showing the migration of KG1a cells within chemotaxis tissue culture plate 
+/- HS5 stromal co-culture and the addition of 60μg of HS5 or AML derived exosome. The 
effect the addition of exosome had on cell proliferation (A) and the migratory capacity of the 
KG1a cells are shown (B).  
In order to investigate the protective effects of exosomes, a tissue culture assay was 
set up using primary AML cells incubated with and without the addition of exosomes 
as outlined in 4.2.3.3. Following treatment with the drug Pacritinib; a FLT3 inhibitor, 
the EC50 of the cells incubated with exosomes was significantly increased showing 
the protective effect exosomes exert upon primary AML cells (Figure 4.17A). 
 
ERK1/2 is a known key regulator of stromal:AML protection identified by previous 
work in our group and several known studies (Marrin   et al. 2014; Yang et al. 2014). 
When primary AML cells were incubated +/- HS5 stromal co-culture and treated with 
increasing doses of Pacritinib, western blotting with ERK1/2 antibodies showed a 
dose dependent knockdown of ERK and pERK. This knockdown is less effective 
when AML cells are co-cultured with HS5 cells, showing the protective effects of 
stroma on ERK targeted drug treatment (Figure 4.17B). 
 
KG-1a co-cultures +/-HS5 stromal cells were set up as previously described with the 
addition of a potent MEK inhibitor (MEKi) - PD0325901 (Sigma Aldrich, Dorset, UK) 
(Figure 4.17C). Following harvest of both supernatants and whole cell fractions, 
western blots were carried out for ERK1/2 detection.  As expected, KG-1a whole cell 
lysate (WCL) showed the presence of ERK and with addition of MEKi this was 
knocked down. ERK could not be detected in KG1a derived exosomes. When KG-1a 
was in stromal co-culture with HS5, ERK was present within the control fraction of 
both the whole cell lysate and the exosome fractions, suggesting co-culture stimulates 
ERK containing exosomes. This increase in exosomal ERK was knocked down with 
MEKi treatment in both the cell and exosome fractions. CD81 was used as a marker 
for exosome and GAPDH as a housekeeping marker for exosome and WCL.  
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Figure 4. 17 Chart showing the effect of FLT-3 inhibitor (Pacritinib) on primary AML cells co-
cultured +/- exosome **p = 0.0026 (A) Western blot showing the dose dependent effect of 
Pacritinib on MV411 cells cultured +/- HS5 cells on ERK expression (B). Western blot of KG-
1a cells incubated +/-HS5 cells and MEK inhibitor (MEKi)  PD0325901  added at 10μM and 
100μM. Exosome (Exo) and whole cell fraction (WCL) were extracted post 48h incubation and 
probed using ERK (42-44kDa) CD81 (22-26kDa) and GAPDH (37kDa) antibodies (C). 
In order to confirm my observations in primary patient material tissue culture assays 
were set up using HS5, NBM, diagnostic and post-BMT derived exosome 
preparations to assess functional effects (Figure 4.18A-D). Results across a cohort 
of four patient samples showed a significant increase in cell proliferation following 
addition of exosomes. The source of exosome preparation was extraneous to 
proliferative effect.  
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Figure 4. 18 Primary AML cells (n = 4) were co-cultured with HS5 stromal cells in the presence 
of 60μg/ml HS5, normal bone marrow (NBM), AML diagnostic and post-BMT derived 
exosomes. Cell proliferative effects were analysed using flow cytometry following 48h 
incubation. 
To investigate the effects of exosome addition compared to stroma alone in primary 
AML samples, Figure 4.19 shows changes in proliferative response in three primary 
AML samples. A significant increase in proliferation was observed for all co-cultured 
with HS5 compared to control alone. Exosome addition gave variable responses 
amongst primary AML blasts. AML 1 and 2 both showed that although exosomes 
increase proliferative effect, the impact of the stromal effect itself is stronger than 
exosomes at encouraging growth. AML 3 however shows that even in the presence 
of a modest stromal effect, the addition of exosomes can further boost the proliferative 
response. 
 
Figure 4. 19 Primary AML samples were co-cultured +/- HS5 cells and +/- 60μg HS5 derived 
exosome over 48h to compare effects of stromal vs exosome proliferative effect (AML1 and 
AML 3 ** p=0.0036, AML 2 * p=0.0464) (n=3).  
 
The effects of increasing stromal exosome concentration on primary AML blasts was 
carried out in 48h co-culture assays +/- HS5 and the addition of 0-120μg of post-BMT 
derived exosomes. Flow cytometry was used to separate the adherent and 
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suspension fractions and measure cell proliferation (Figure 4.20A) The effect of 
adding BMT derived stromal exosomes into culture produced a significant increased 
proliferative effect, even without stromal support and within the suspension fraction 
of co-cultured plates in a dose dependent manner. Adherent fractions showed 
minimal increased effects at high doses of exosomes suggesting adhesion is not 
increased with BMT exosome preparations.  
 
Furthermore, the effects of NBM, diagnostic and post-BMT derived exosomes on two 
AML samples alone and in co-culture showed a trend for increased cell proliferation 
following all exosome additions, although AML 2 showed a more pronounced effect 
when exosome and stroma were present together (Figure 4.21).  
  
Figure 4. 20 Primary AML sample was incubated +/- HS5 stromal with 60μg of AML post-BMT 
(+Post BMT exo) and 120μg AML post-BMT (+post BMT high dose) derived exosome 
incubated in culture for 48h. Suspension and adherent co-culture fractions were separated 
and analysed by flow cytometry. Significant difference was observed for both co-culture and 
alone between control and addition of exosome (*p=<0.0001, n=3) 
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Figure 4. 21 Primary AML samples were co-cultured +/- HS5 cells with 0-60μg of NBM, AML 
diagnostic and AML post-BMT derived exosomes added to culture. Post 48h incubation cell 
proliferation was assessed using flow cytometry (n=3). 
 
The effect of exosome addition on primary AML suspension and adherent fractions 
was investigated (Figure 4.22) and within the suspension fractions (A-C) addition of 
exosome was seen to enhance cell proliferation in most cases, an exception is seen 
for one AML (Figure 4.22A). Adherent fractions showed no proliferative benefits from 
addition of exosomes (Figure 4.22D-F). 
 
Figure 4. 22 Primary AML samples were co-culture with HS5 and incubated for 48h with 60μg 
of NBM, AML diagnostic and AML post BMT derived exosomes and separated into suspension 
(A-C) and adherent (D-F) fractions. Analysis by flow cytometry plotted at day 0 (D0) and day 
2 (D2) post exosome addition (n=3). 
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Finally, the effects of exosome addition on HS5 cells were analysed within primary 
AML co-culture and found that it provided minimal proliferative support, post-BMT 
derived exosomes were the only exosome sub-type to increase cell proliferation, 
although not significantly (Figure.4.23).  
 
 
Figure 4. 23 Chart showing the effect of adding 60μg of NBM, AML diagnostic, AML post-BMT 
derived exosome on HS5 stromal cells over 48h incubation period (n=3).  
In summary: 
- Luminex profiling identified changes in target expression between NBM, 
diagnostic and early-mid and late post-BMT, highest levels observed in 
diagnostic samples 
- Overall lower expression of targets in exosome compared to supernatant 
- Post-BMT samples showed high expression of immune related targets  
- Expression of leukaemic related mIRs showed an increase in levels within 
diagnostic and post-BMT samples compared to NBM. 
- MV411 cell lines show increased proliferative effect upon addition of 
exosomes in culture. 
- Exosome addition to KG1a cell line co-culture showed a small increase in 
proliferation and migration which increased on stroma within the adherent 
fraction. 
- Addition of exosomes within KG1a stromal co-culture induced a survival 
advantage involving ERK signalling 
107 
 
- Primary AML cells show an increase in proliferation upon addition of 
exosomes which varies between samples 
- Exosome addition shows more effect on proliferation within suspension 
fraction of stromal co-cultured primary AML cells. 
4.4 Discussion 
Luminex analysis showed that cytokine profiles of exosome fractions contained fewer 
targets at detectable levels compared to the much more diverse cellular derived 
content of the supernatant fraction. Published work comparing the cytokine content 
of exosomes to that of their cellular counterpart is sparse, as far as I am aware this is 
the first time this has been shown in AML. There are studies that show differences 
between plasma content and equivalent exosome cytokine levels, and this is reported 
to be target dependent with substantial differences seen between both (Prieto et al. 
2017; Kodidela et al. 2018).  
A study involving head and neck cancer compared protein content between 
exosomes and equivalent cell lysate from various cell lines, and found that the 
exosome profile did not always correspond to that of the parental line but, overall 
expression levels were lower within the exosome samples, agreeing with my 
observations (Ludwig et al. 2018). A likely explanation for lower levels of protein 
expression within the exosome fractions could be due to their small size and  very 
heterogeneous content compared to the secretory samples. The molecular content 
of exosomes originating from different types of cell and biological fluids has been 
identified to contain proteins, nucleic acids, lipids, metabolites as well as thousands 
of different macromolecules (www.exocarta.org), this is all contained within the 
exosome preparation and could impact on downstream analysis and result in a lower 
level of expression compared to the less heterogeneous secretory sample.  
When cytokine levels were compared between exosomes originating from AML cells 
to normal bone marrow, a heightened expression of targets was seen in the diseased 
cells. This could perhaps be explained by the important role exosomes originating 
from MSC cells play in remodelling the bone marrow microenvironment into a 
malignant niche. It is known that MSC gene expression and functionality in AML is 
different to that from healthy individuals, and exosomes have been shown to play a 
major role inducing these microenvironmental changes in AML (Barrera-Ramirez et 
al. 2017). Consequently, it is probable that exosomes originating from AML derived 
MSCs would show higher expression of numerous targets involved in bone marrow 
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microenvironment remodelling, compared to normal derived MSCs which are only 
likely to play a role in maintaining homeostasis within a stable BM-niche.  
Cancer derived exosomes are known to be enriched in molecules which help support 
disease proliferation, metastasis and immune surveillance avoidance (Hong et al. 
2014a), exosomes derived from MSCs within a malignant microenvironment would 
show similar enrichment which could further explain the high levels of target protein 
detected. 
The difference in overall abundance levels of targets and their function between 
supernatant and exosome is perhaps due to the heterogeneity of supernatant content 
compared to the more specific and targeted content of exosomes. It is known that 
exosomes function as communication vehicles and their contents can differ from that 
of the parental cell, making it logical that the signalling proteins it transports would be 
more specific to a function of the environment it resides (Willms et al. 2016).  
Further investigation into the breakdown of Luminex analysis using hierarchical charts 
shows a clear division of expression of targets within exosomes, there was much 
higher expression in NBM and diagnostic samples compared to both early-late post-
BMT. One of these targets was C-kit which when analysed independently showed 
significantly lower expression in the majority of post-BMT samples. C-kit mutations in 
t(8;21) AML are monitored at MRD level for relapse in post-transplant cases as 
mutated cases are more likely to relapse compared to unmutated. The lower levels 
of C-kit expression seen here in post-BMT could signify a positive clinical outcome 
(Ossenkoppele et al. 2016), and may reflect a novel level of regulation from the cell 
surface into exosomes. 
Overall expression levels of targets within the exosome fraction (Figure 4.6) identified 
VCAM-1 as the most highly abundant target present within all categories of sample 
type and highest within the NBM. VCAM-1 is a protein which acts as a mediator of 
the adhesion between lymphocytes, monocytes, eosinophils and basophils to the 
vascular endothelium where it is also involved in leukocyte/endothelial cell signal 
transduction. It is unsurprising that it’s seen in such high levels in NBM, as it is an 
important requirement within a normal functioning bone marrow niche.  
The down regulation of VCAM-1 observed in the post-BMT has previously been 
observed within work involving ALL, bone marrow stromal cell cultures post -
transplant showed significantly reduced expression compared to normal donor bone 
marrow. Further investigations show a correlation between B-cell precursor growth 
and adhesion and CD106 expression, it is thought that this could be why recovery is 
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delayed post-transplant, as the capacity of transplanted stromal cells is impeded by 
low B-cell lymphopoiesis (Dittel and LeBien 1995).  
Another adhesion molecule ICAM-1 is highly expressed in all sample types although 
lower levels were observed in NBM and later stage post-BMT. ICAM-1 binds to the 
surface of leukocytes and becomes induced under inflammatory conditions aiding the 
migration of leukocytes and activation of T-cells (Dustin et al. 1986), the higher levels 
observed in diseased and early post-BMT could reflect the heightened immunological 
environment expected in these samples compared to normal. Late post-BMT reflects 
a stabilization of the inflammatory environment towards normal bone marrow levels 
along with an increase in adhesion related molecules suggesting a recovery post-
transplant, the stromal microenvironment becoming more hospitable to transplanted 
stromal cells forming a niche with the aid of various adhesion molecules.  
Early post-BMT exosomes showed high levels of IL4 and IL10, these are both 
involved in immunological function and within an early post-BMT environment you 
would expect immune response to be heightened during immune constitution, which 
varies in timescale from patient to patient. Recent research has identified IL-4 as a 
selective inhibitor of AML cell growth and survival, which could be a useful aid within 
a post-BMT environment to suppress minimal residual disease and could be used for 
monitoring purposes. (Pena-Martinez et al. 2018). 
IGFBP-3 was more highly expressed within post-BMT exosome samples compared 
to other sample stages. IGFBP-3 functions as an aid to cell survival and differentiation 
and is dysregulated in many cancers. IGFBPs have been identified as playing an 
important role in tumour proliferation, and studies involving adolescent AML and ALL 
have shown that important changes take place within the IGF (insulin-like growth 
factors) system following haematopoietic stem cell transplant, as they play an 
important role in the proliferation rate of transplanted bone marrow. This could help 
explain the heightened levels observed in post-BMT (Dawczynski et al. 2003).  
Further analysis of targets identified within the exosome fraction (Figure 4.7-10) 
showed that within post-BMT samples high levels of targets mostly associated with 
immunological and chemoattract functions were observed, and NBM showed a higher 
expression of targets associated with survival/differentiation and adhesion. This 
observation was further confirmed within pie chart analysis of target functional groups, 
(Figure 4.6) early post-BMT showed very clearly that the highest expression of targets 
were those associated with an immunological function, and interestingly mid-late post 
BMT reverts to a profile more associated with survival and adherence seen in 
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diagnostic and NBM. This bias towards immunomodulating targets seen early post-
transplant suggests that exosomes might be involved in the transfer of soluble factors, 
which have been reported to manipulate T-cell function that could lead to the aid of a 
hostile or supportive environment for AML (Lamble and Lind 2018). 
Comparison between exosome and supernatant expression profiles (Figure 4.8-10) 
were very different, and only showed a similar profile within the targets associated 
with adhesion and targets BMP-4 and Protein-S both associated with 
survival/differentiation. Apart from these exceptions the expression profiles of 
exosomes were very different to supernatant between patient sub-categories. 
This was further confirmed within the pie-chart analysis (Figure 4.6). Results showed 
that supernatant expression profiles of NBM and diagnostic samples showed a 
dominance of survival/differentiation which differed greatly to exosome profile of 
adherence. Post-BMT however, showed more similarities between exosome and 
supernatant. NBM and diagnostic profiles within the supernatant fraction showed very 
high levels of osteonectin, the highest of which were seen in diagnostic samples and 
absent from early post-BMT and at low levels within mid-late-BMT. Osteonectin is 
involved in cell differentiation and regulates the adhesion of osteoblasts and stromal 
support, and has been strongly implicated as a poor prognostic marker of AML. 
Research has shown that it promotes leukaemic cell growth and could explain it’s 
prominence within the diagnostic samples (Alachkar et al. 2014). 
The miRNA content of MSC derived exosomes for all sample sub-sets  was assessed 
for the expression of mIR155 and mIR1246 (Figure 4.13), these targets were selected 
as both have been shown to be exported in exosomes and correlated with presence 
of leukaemia (Hornick et al. 2015).  
My work showed that expression of mIR1246 was significantly increased in samples 
of post-BMT and diagnostic origin compared to NBM. This agrees with previous work 
that has shown an increase in association with presence of leukaemia (Hornick et al. 
2015). Previous work using an AML-engrafted mouse model showed that mIR1246 
expression from exosomal miRNA increased in correlation with disease progression 
(Abdelhamed et al. 2019), this could help explain the large spread of data I observed 
within the post-BMT samples, perhaps reflecting the heterogeneity of disease 
recovery post-transplant. Previous work showed that EV’s enriched with mIR1246 
were transferred from AML cells to HSCs leading to DNA damage and dysregulation 
of the protein kinase S6RP and an associated induction of p53- dependant 
quiescence (Abdelhamed et al. 2019). The quiescence imposed upon residual HSCs 
111 
 
within the leukaemic niche could be a good indicator of MRD and another explanation 
for the varying levels of expression I observed post-BMT. The link between mIR1246 
and dysregulation of p53 has been seen in numerous other studies including the B-
cell dysfunction within systemic lupus erythematosus and the inhibition of the Down 
Syndrome associated gene DYRK1A expression which has been seen to occur via  
p53 induction of mIR1246 (Zhang et al. 2011; Luo et al. 2015).  
Another study showed an association between increased oesophageal squamous 
cell carcinoma with mIR1246 expression and interestingly when they compared 
cellular and exosomal expression levels they found much higher levels within the 
content of exosomes, indicating the important secretory role exosomes play 
(Takeshita et al. 2013). This study highlights the importance of assessing exosome 
mIR content as opposed to cellular as it could provide more accurate information 
regarding disease progression. 
mIR155 has been associated with dysregulation with many cancers (Tili et al. 2010; 
Donnem et al. 2011; Lanczky et al. 2016), in AML it is thought to be involved in 
regulating genes which play active roles in promoting leukaemogenesis (Hornick et 
al. 2015). My results agree with previous research and show a trend of increased 
expression within the diagnostic and post-BMT samples compared to NBM. 
Both mIRs profiled here have shown in previous studies an association with B-cell 
dysregulation, mIR155 transfer from leukaemic cells via gap junctions has been 
shown to directly transform healthy B-cells to a malignant form (Tili et al. 2009). It has 
been reported that mIR1246 has been linked to p53 expression resulting in abnormal 
B-cell function (Luo et al. 2015). The increased expression observed of both mIRs in 
post-transplant samples along with increased levels of immunomodulatory targets 
highlighted within the Luminex analysis provides more evidence of the role exosomes 
play in mediating immuno-modulatory effects within a post-transplant environment. 
The functional effects of exosomes within a cell culture environment varied depending 
on cell source (Figure 4.14). When using MV411 cells a significant increase in 
proliferative effect was observed when exosomes were added to a stromal co-culture 
environment. This effect was reduced for KG-1a cells, with only a small proliferative 
advantage observed which was not dependent on exosome source, illustrating that 
exosomes can offer a proliferative advantage across different cell types irrespective 
of parental cell, this agrees with previous research which has shown that cancer cells 
can use exosomes to manipulate their microenvironment to gain survival advantages 
(Clayton 2012; Corrado et al. 2014; Zhou et al. 2016).  
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Further investigation into exosomal effects within KG-1a stromal co-culture (Figure 
4.15) revealed addition of exosomes had an increased proliferative effect on cells 
within the adherent fraction compared to those in suspension, suggesting that the 
increase in cell number was driven by adhesion rather than a proliferative effect of 
exosomes (Taverna et al. 2014; Tang et al. 2016).  
The effect of exosomes on the migration of KG-1a cells (Figure 4.16) showed minimal 
advantage, and the presence of stroma created the biggest drive in migration, this 
could be explained by the higher concentration of various soluble factors and 
cytokines secreted by the HS5 stromal cells in culture compared to the relatively small 
exerted by exosomes. The small increase in total cell numbers upon addition of 
exosomes within the stromal environment show that although exosomes do have an 
impact on cell proliferation, it is minimal compared to the effect of stroma in this 
context and not enough to stimulate a migratory response. This is likely to be cell type 
dependant as a previous study involving CML showed that cell migration was 
stimulated by exosomes but it was the exosome cross-talk with stromal cells that 
stimulated the release of IL-8 and increased  migratory effect, this could help explain 
why migration is only seen here when in presence of stroma (Corrado et al. 2014). 
The exosome induced cell survival advantage in KG-1a cells was further investigated 
using western blotting to analyse pro-survival ERK signalling in exosomes of KG-1a 
cells in co-culture (Figure 4.17). Stromal induction of ERK in exosome fractions was 
detected in co-culture and could be abrogated through treatment with MEK inhibitors. 
ERK1/2 signalling is known to become frequently activated in AML co-cultures and 
provides pro-survival functions associated with drug resistance (Lunghi et al. 2003). 
The source of the ERK expressing exosomes is unknown, it is possible they originate 
from HS5, KG1a or both cells but in order to determine this, it would require separation 
of these post-culture which is currently limited by technical difficulties. Irrespective of 
exosomal origin, those released within a stromal co-culture environment are different 
to those within a single culture system and induced a survival advantage in KG-1a 
cells. 
The functional effect of exosomes on primary AML cells was different to that seen in 
cell lines (Figure 4.18). A significant increase in proliferation was observed upon 
addition of exosomes which was AML specific and although stromal support did offer 
a proliferative advantage to AML cells this was not always stronger than the effect of 
exosome alone, this variability could be as a result of the heterogeneous nature of 
AMLs which have been shown to exhibit inherent cytokine independence deeming 
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them less reliant on stromal support and survival in co-culture (Yang et al. 2014; 
Huang et al. 2015).  
The effect of exosomes within primary co-culture showed a more proliferative effect 
exerted on cells in suspension compared to adherent, this was shown very clearly 
within the suspension fraction of one AML sample in a dose dependent manner 
(Figure 4.20). This could be due to the larger cell surface area and increased 
possibility of interaction of cells in suspension with circulating exosomes. Those within 
the adherent fraction would become immobilized when connected to the stromal layer 
and direct cell to cell contact with stromal cells could provide the adherent cells with 
sufficient support. A previous study involving breast tumour cells showed that 
increased exosome uptake and arrangement on cell surface enhances call adhesion 
and proliferation (Koumangoye et al. 2011). The presence of exosomes within a co-
culture environment could be stimulating more adhesion and proliferation, which is 
why we see an enhancement for both cell lines and primary cell culture. Cell lines 
may show a reduced uptake of exosomes compared to primary cells due to the 
downregulation of numerous cell surface receptors that takes place when cells are 
immortalised, cell lines are characteristically more self-sufficient and so don’t require 
the same level of support supplied to primary cells via exosomes. A way to test this 
theory would be to culture cell lines within serum starved conditions and measure the 
effect of exosome addition. 
Future plans also include running matched plasma samples from AML patients. 
Plasma will contain a plethora of molecules originating from numerous cell subtypes 
so would be interesting to see whether the dominance of a cell differentiation related 
function is reflected, and a commonality shared between the malignant or healthy 
supernatant and exosome fractions. Cohorts could also be examined for 
molecular/morphological  relapse in order to determine whether candidates 
previously identified segregate with these groups at earlier time points. 
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5 Chapter 5 Discussion 
The study of extracellular vesicles is a popular field of research with much still to 
discover, we know that they play an extremely important role in many aspects of 
human disease and have potential use as a monitoring tool, biomarker and 
therapeutic. The aim of this study was to investigate how important extracellular 
vesicles are as promotors of residual AML survival and better understand their role in 
creating a hostile microenvironment that favours disease survival. Identification and 
characterisation of differences between exosomes derived from diseased, normal 
and post-BMT AML has the potential to identify biomarkers and early relapse.  
Characterisation of exosome material highlighted significant differences between 
patient sub-sets of MSC derived exosomes. Diagnostic AML samples showed an 
elevated level of exosome production compared to other sample types, which 
corresponds to disease presence and is significantly higher than normal bone marrow 
production which is to be expected as similarly seen in previous work (Taylor and 
Gercel-Taylor 2008; Rosell et al. 2009; Jenjaroenpun et al. 2013). Interestingly early 
and late post-BMT samples displayed different levels of exosomes, early-BMT more 
similar to the lower levels seen in NBM and late-BMT showed a large spread of data 
unlike any other sample type. These observations suggest that for some patient’s 
recovery post-transplant is not stable, an important finding which warrants further 
investigation with an expansion of sample numbers and correlations with clinical 
presentation of relapse or graft failure. 
Recent work has confirmed that exosome secretion from AML blasts leads to a 
complete remodelling of the bone marrow niche into a leukaemia permissive 
environment while suppressing the growth of normal haematopoiesis, this reflects the 
characterisation work I carried out on MSC derived exosomes which showed higher  
numbers within diseased and post-transplant samples compared to normal (Kumar 
et al. 2018). The suppression of normal haematopoiesis via blast derived exosomes 
has also been seen in work carried out by Namburi et al which showed the presence 
of exosomes in AML patients in CR suppressed normal haematopoiesis (Namburi 
2018). This could help explain the variability seen in post-BMT as these samples 
could contain BM-ME at different stages of recovery and the higher levels of 
exosomes observed could signify the sustained repression of normal functional 
behaviour of the HSCs residing there. Work carried out investigating the impact of 
EVs within the tumour microenvironment of breast cancer showed that a transfer of 
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miRNA via EVs transformed surrounding normal fibroblasts into cancer supporting 
cells, this reflects another route by which exosomes could become involved in 
transforming a normal BM-ME into a malignant one (Vu et al. 2019). 
 The large variability I observed within the late-BMT sub-set of samples could  also 
be an early indicator of patient transplant success or failure, but considering the 
heterogeneity of AML this could indicate the variation in time taken for each patient 
to recover normal homeostasis within the bone marrow microenvironment following 
transplant. It is known to take up to two months to recover haematological function 
(Pavletic et al. 1998), and up to 30 days for innate, and up to 1 year for adaptive 
immune reconstitution (Ogonek et al. 2016) but this is variable between patients.  
Previous work involving a murine heart transplant model showed that monitoring of 
exosome numbers can give an indication of acute rejection, this study showed that 
an increase in donor exosomes which were identified by labelling with anti-H2-Kd-
antibody and assessed using a nanoparticle detector showed a  correlation with a 
reduction in graft rejection (Habertheuer et al. 2018). The positive link between 
exosome presence and increased transplant success has been reported in numerous 
in vitro studies which show that exosomes including those originating from Treg cells, 
suppress inflammatory response and allograft tolerance (Peche et al. 2006; Kim et 
al. 2007; Agarwal et al. 2014). These could help explain observations in my work and 
give an indication of graft progression within patients. The effect of exosomes on 
transplant is not always positive, a recent in vivo study showed that donor exosomes 
transferred MHC-complex to antigen presenting cells which initiated skin, heart and 
islet graft rejection (Marino et al. 2016). It is clear that exosomes are involved in many 
processes, some will have a positive impact and others a negative on transplant 
success.  
Previous work has shown that the miRNA contained in exosomes can differ to that of 
the parental cell but in the case of cancerous cells can provide information regarding 
potential gene dysregulation, which correlates with disease progression making it an 
attractive potential diagnostic tool (Mittelbrunn et al. 2011; Hornick et al. 2015; 
Barrera-Ramirez et al. 2017). I found that miRNA content of exosomes was elevated 
in diagnostic samples compared to normal and post-BMT, it has previously been 
reported that the amount and composition of exosomal miRNA differs between 
diseased patients and healthy individuals (Zhang et al. 2015). A recent study used a 
human-into-rat xenogeneic heart transplant model to investigate the miRNA content 
of exosomes produced by transplanted cardio related cells, they isolated exosomes 
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from blood and compared it to exosomes extracted from the same cells cultured in 
vitro, and showed that their miRNA contents differed, the in vivo derived exosomes 
contained miRNA linked to miRNA recovery (Saha et al. 2019). Many cancer studies 
involving the profiling of exosomal miRNA content has shown those originating from 
malignant origin contained higher concentrations of differentially expressed miRNA 
compared to healthy individuals (Taylor and Gercel-Taylor 2008; Li et al. 2016; 
Bhome et al. 2017). A study involving breast cancer showed that exosomes derived 
from BM-MSC cells contained much higher levels of miRNA compared to normal cells 
and specifically overexpression of mIR23b that induced dormant phenotype leading 
to promotion of breast cancer cell dormancy within a metastatic bone marrow niche 
(Ono et al. 2014). Previous work involving AML cell lines showed an enrichment of 
exosome derived miRNA and in vivo mouse model work showed that miRNA from 
exosomes could help predict relapse in AML (Huan et al. 2013; Hornick et al. 2015).  
These studies illustrate how the microenvironment of malignant and transplanted 
cells has a direct impact on exosome number, concentration and content which is 
mirrored in the differences I have observed in AML and indicates the effect  of genetic 
material transfer via exosomes can have and transform the microenvironment of 
these cells and improve their survival. 
Several studies have reported the presence of miRNA in AML derived exosomes and 
the effect this has on compromising haematopoiesis and regulating communication 
within the tumour microenvironment (Hornick et al. 2016), the preliminary mIR 
profiling I carried out reflected this showing an increased expression of mIR1246 and 
mIR155, both associated with leukaemic state. Going forward I would like to profile 
these AML patients to try to identify corroborating changes in gene expression, similar 
work has been carried out by Barrera-Ramirez et al,  but in a different context 
(Barrera-Ramirez et al. 2017).  
My work showed no correlation between MSC size with exosome and miRNA yield 
indicating the differences observed were indeed disease stage specific and not simply 
a product of the area of the cells, to the best of my knowledge this is the first time a 
report on RNA yield of MSC derived exosomes has been made. Further studies to 
quantify the degree of basal differentiation (osteoblast, adipocyte, primitive) of the 
different stromal layers would be of interest to determine whether heterogeneity has 
impact on exosome production, this work will be carried out in subsequent projects. 
Increased exosome number did show some association with an increase in miRNA 
yield, but as previously stated this is not thought to be necessarily important, as it is 
known that only a fraction of miRNA present within the parental MSC  goes on to 
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become transferred by the MSC exosomes and the content of miRNA is heavily 
influenced by the microenvironment of the cells, therefore the amount of miRNA being 
carried as cargo may not reflect the downstream mechanism of action generated (Bell 
and Taylor 2017). 
A recent publication involving MSC derived exosomes commented on the lack of 
reported information to date on RNA yield from MSC exosomes (Toh et al. 2018). 
One of the challenges within the extracellular vesicle field is producing adequate 
exosome yield, and although sample size was small I showed significant differences 
in exosome numbers and yield based on disease stage, I believe my work has gone 
some way to investigate exosomes derived from MSCs. An expected standard 
concentration of exosome protein and miRNA harvested from MSCs still requires 
further standardization of the exosome isolation process and is an area of ongoing 
concern outlined by the International Society for Extracellular Vesicles. 
I previously discussed in Chapter 3 that the post-BMT samples that showing higher 
levels of exosome release could be an early indicator of GvHD. Recent studies have 
shown the use of exosomal miRNA profiles in helping to make a  molecular diagnosis 
post-transplant,  they showed that certain mIRs associated with inflammation and 
immune response were upregulated within patients showing late onset GvHD and 
that exosomal miRNA could also have a potential use as a biomarker for GvHD 
prediction (Yoshizawa et al. 2018). Whilst this study examined a small number of 
relapse samples, it would be interesting for future work to follow up on serial patient 
samples that showed higher levels of exosome release post-BMT to investigate a link 
to relapse or GvHD. As GvHD is present in approximately 30% of samples at any one 
time point post-transplant, further investigation is needed with larger sample numbers 
enabling disease progression and associated exosomal changes to be tracked.  
Recent research has brought into doubt the commonly held belief that miRNA is the 
driver of exosomal functional behaviours, they state that it is more probable that 
protein content of exosome cargo is more likely to propel mechanism of action, it is 
suggested that the quantities of miRNA present in MSC derived exosomes are not 
sufficient to bring about a biologically relevant response unlike proteins which they 
illustrate are more commonly present at high enough levels to illicit a mode of action 
(Toh et al. 2018). I investigated the protein content of exosomes using Luminex 
analysis and found there was an overall higher expression of target protein levels 
within AML patients compared to healthy individuals, the experiment was carried out 
using normalised exosome numbers for each patient analysed so this increase in 
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protein expression signifies a difference in protein loading of exosomes as opposed 
to increased exosome release which has been observed in many other studies. This 
increase in protein levels of cancer derived exosomes has been seen in many other 
cancer types. This higher level of protein content observed could be explained by as 
previously suggested, it functioning as a more prominent driver of exosome mode of 
action. 
Hierarchical clustering showed that within the exosome samples was a clear 
separation of target expression between normal and diagnostic with post-BMT 
samples. In terms of the type of dominant protein species, the diagnostic and normal 
samples showed a dominance of adherent related targets compared to a dominance 
of immunology based functions in early BMT changing to a survival/differentiation 
profile in mid-late BMT.   
The leukaemic environment in AML is highly immunosuppressive and early post-
transplant it would not be unexpected to see high expression of targets associated 
with immune response as the patient would still be in an immune suppressed state, 
the change in expression profile to one of survival/differentiation in some mid-late 
BMT samples shows that the patients are recovering a more supportive environment  
for haematopoietic  growth. It is unexpected to not see higher levels of immune related 
targets within the diagnostic samples as previously mentioned, this would also be an 
immunosuppressed environment, a possible explanation for this might be that the 
malignant environment has already undergone changes to compensate for this and 
so less transfer of information via exosomes is required, unlike that seen in post-
transplant which is undergoing much change within the microenvironment alongside 
the effect of immunosuppressants requiring more intercellular communication.  One 
of the targets I identified within the post-BMT samples as highly expressed is IL-12 
which has been associated with the activation of NK-cells and increased anti-
leukaemic activity, it has also been suggested that IL-12 activated NK-cells help 
prevent GvHD taking place by inhibiting the proliferation of donor T-cells while still 
maintaining a GvL effect, improving the OS of mice (Ewen et al. 2018).  
Although both VCAM-1 and ICAM-1 were identified as being highly expressed within 
all stages of patient exosome samples, this is not unexpected as all cell types within 
the bone marrow microenvironment require high levels of adherence in order to retain 
healthy or diseased cells and create the associated hospitable niche. The expression 
of these targets was observed to be higher within the diagnostic samples compared 
to NBM. This was particularly apparent within the validation western blots that showed 
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a complete absence of ICAM-1 within the two normal exosome samples in contrast 
to a clear upregulation within the diagnostic and post-BMT samples suggesting 
significant remodelling and potential for adhesion to the niche in these samples. Other 
studies have showed similar results, work carried out using breast cancer cell lines 
showed that cancer derived exosomes associated with the protein fetuin-A and 
histone H2A which resulting in exosome mediated adhesion and cell spreading 
(Nangami et al. 2014). Work involving mature dendritic cells showed that secreted 
exosomes were enriched in ICAM-1 functioning as important adhesion receptors 
which resulted in the efficient activation of T-cells (Segura et al. 2005). Exosomes are 
reported to play a major role in transforming the AML BM-ME into more hypoxic 
conditions, which can result in the upregulation of TGF-β1 expression and 
subsequent AML blast proliferation. This exosomal driven chain of events can lead to 
activation of CXCR4/SDF-1 pathway, immune cell suppression and increased levels 
of VCAM-1 and ICAM-1 such as I observed which aid regulation of cell adhesion and 
remodelling of the BM-ME (Chen et al. 2013; Ohyashiki et al. 2016).   
An increase in ICAM-1 within the post-BMT samples could also be explained by the 
role it plays in bringing about an immune response. Previous studies have shown that 
B-cells actively uptake exosomes and interact with those exosomes containing MHC-
class II and ICAM-1 originating from mature dendritic cells. Leukocyte function 
associated antigen-1 (LFA-1) is used by activated T-cells for binding the DC 
exosomes and it is the interaction between LFA-1 and ICAM-1 which is critical for 
priming naïve T-cells and the subsequent antigen specific immune response triggered 
(Ferguson Bennit et al. 2019). Future work could involve investigating the presence 
of these activated cell types within the bone marrow to monitor changes in the active 
T-cell population. This could be accomplished by monitoring the presence of T-cell 
associated molecules like LFA-1 and MHC within serial AML patient plasma samples 
which we have banked in storage. Elevated levels of ICAM-1 within AML has been 
reported in previous work, ICAM-1 commonly present on leukaemic blasts leads to 
increased adhesion of these cells within the BM niche leading to a series of events 
which include protection, quiescence and chemoresistance which is commonly 
followed up by AML blast detachment, increased proliferation and relapse (Gruszka 
et al. 2019). The adhesion properties supplied by ICAM-1 and other related molecules 
give rise to an acquired therapeutic resistance and could possibly be used as a good 
indicator of disease relapse. 
TIMP-1 (Tissue inhibitor of metalloproteinase 1) was identified by Luminex and ELISA 
as having higher levels within the post-BMT exosome samples, recent studies have 
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shown it to have a crucial role in immune regulation as well as links to inflammatory 
and autoimmune disorders which could explain it’s increased prevalence in post-
BMT. Interestingly, a recent study investigated potential biomarkers for GvHD in post-
alloHSC transplant patients using plasma from a variety of haematological disorders, 
within a large cohort they identified only TIMP-1 as a viable potential biomarker. A 
correlation between TIMP-1 and GvHD risk was identified and showed that patients 
with high TIMP-1 levels were twice as likely to experience GvHD compared to those 
patients with normal levels (Shin et al. 2019). Monitoring GvHD is an important way 
of also assessing the anti-leukaemic effect of GvL as previous work has shown that 
the T-cells of the marrow graft are responsible for both initiating GvHD and enhancing 
GvL effect (Horowitz et al. 1990). The prevention of GvHD while enhancing the 
beneficial aspects of GvL is the most effective way of reducing the chance of 
leukaemic relapse after bone marrow transplant (Tsukada et al. 1999). 
Studies have also shown an increased level of TIMP-1 within BM plasma of AML 
patients compared to normal, they demonstrated that TIMP-1 is involved in 
modulating leukaemic blast migration and survival (Forte et al. 2017). Another study 
showed that exosomes derived from MSCs contained elevated levels of TIMP-1 and 
supported tumour function when introduced into a xenograft assay involving MCF7 
breast cancer cells.  Once again, the observations shown in the exosome fraction 
were not reflected within the supernatant. 
The difference between exosome and supernatant fractions within the analysis of 
target abundance isn’t large within the post-BMT subset both show an increase in 
levels of immunology related targets at early stage changing at late stage to become 
more survival/differentiation related. When analysing specific targets a more defined 
difference between exosome and supernatant becomes apparent especially within 
those immunology related targets; TIMP-1, ERBB2, IL-12 and IL-4.The cargo of 
exosomes is known to contain information that differs to that of the parental cell 
(Hornick et al. 2015) and is thought to be directed and specifically targeted to acceptor 
cells in order to bring about a phenotypic change (Ciardiello et al. 2016). Supernatant 
fractions consist of a very heterogenous mix of metabolites, growth factors and matrix 
proteins which although give useful information regarding the microenvironment of 
the residing cells this doesn’t provide details of the targeted and specific changes 
being induced as shown by the exosome contents. There is strong evidence showing 
the strong efficacy MSC secreted factors have in mediating tissue repair and 
regeneration via paracrine methods (Togel et al. 2005; Togel et al. 2007; Xiang et al. 
2009; Park et al. 2012), but the mechanisms are not fully understood and it is known 
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that EVs make up a large portion of the MSC secretions and these effects have been 
shown to have equal potency to those of whole cell MSC administration (Rani et al. 
2015), meaning that the functional effects could in theory be predominantly due to the 
MSC EV secretions.  The exosome results provide a more informative overview of 
intercellular communications and potential functional output and more specifically 
show an increased association with immunomodulatory function, which could become 
an early indication of relapse and signifies the importance of changes observed 
between samples of different origin; normal, diseased or post-transplant. 
Previous studies have shown that MSCs release several soluble factors linked to 
immune suppressive and anti-inflammatory properties these include extracellular 
vesicles which have also been suggested as a potential therapeutic in supporting 
stem cell transplant (Uccelli et al. 2008). Data showed that the advantages of 
exosomes over MSCs are the unlikelihood of immune rejection due to their small size 
and lower expression of histocompatibility molecules, they have also shown to reduce 
or stop GvHD by modulating the immune response and this in combination with HSCs 
could help create a more pro-haematopoietic BM-niche (Reis et al. 2016).  
Luminex analysis highlighted higher levels of ERBB2/HER-2 within the post-BMT and 
diagnostic exosome samples. ERBB2/HER2 is a tyrosine kinase whose 
overexpression is seen in many cancers most commonly as a breast cancer 
oncogene, but also implicated in LSC maintenance and promotion of 
leukaemogenesis (Ufkin et al. 2014). It is known to bring about cellular affects via 
activation of the PI3 Kinase/AKT pathway of which downstream effects can include 
increased expression of ERK and promotion of PD-L1 mediated immune response 
(Hong et al. 2016).  
Within a stromal co-culture setting I showed an increase in ERK expression within 
exosome fractions, this along with the overexpression of ERBB2 seen in diagnostic 
and post-BMT exosomes suggests a potential role for exosomes in conferring this 
dysregulation. It is interesting to observe that the increased levels of ERBB2 is not 
reflected in the supernatant fraction of Luminex analysis, suggesting that mobilisation 
of this molecule and subsequent signalling transduction is due to exosome transfer 
alone. The mediation of intercellular transfer of molecules by extracellular vesicles 
has been identified in numerous studies especially within the PI3K/Akt signalling 
pathway, but as yet not within the post-BMT setting of AML (Gangoda et al. 2015). 
When exosomes were introduced into a stromal co-culture, I observed an overall 
increase in leukaemic cell proliferation along with an activation of ERK. It is widely 
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reported that when myeloid blasts are in contact with stroma many pathways are 
upregulated including ERK (Roccaro et al. 2013; Viola et al. 2016), it has also been 
shown that leukaemic blasts on stroma have influenced the inhibition of FLT3 via a 
combination of soluble factors and direct contact with stromal cells (Parmar et al. 
2011; Yang et al. 2014). 
A previous study investigated inhibitory signals thought to be initiated by blast derived 
exosomes which when co-incubated with NK cells caused a down regulation of 
NKG2D suppressing their function. A mixed population of exosomes were separated 
using CD34+ antibody coated magnetic beads and contents of the different 
populations analysed. They found that the CD34+ blast derived exosomes contained 
content which resembled that of parental blasts, and the enrichment correlated 
directly with the % of blasts in circulation which was not seen in the normal derived 
exosomes, confirming the hypothesis that leukaemic blasts control their exosomal 
cargo and it differs to that of a normal derived exosome (Hong et al. 2014a). This 
technique has been criticised as drawbacks include the difficulty identifying an 
appropriate surface target and antibody which recognises the extracellular domain, 
it’s also possible that due to the heterogeneity of diseased cells that not all will express 
the target antigen and with disease progression this could be lost or the antigenic 
epitope could become masked or blocked leading to low specificity (Taylor and Shah 
2015).  
Separating exosomes would have been helpful within my studies enabling me to 
identify the exact origin of my mixed exosome preparations, this was a limitation and 
going forward pinpointing the origins of specific exosomal populations and their 
individual functional input within a mixed system, would be a useful analytical tool. I 
showed an activation of ERK in exosomes when on stroma although it is unknown 
whether HS5 or leukaemic cell derived exosomes are driving this signal upregulation, 
this observation warrants further investigation and separating exosome populations 
to enable the identification of the origin of the ERK activated exosomes would help 
gain insight into this mechanism of action. 
 
 In order to address the further mechanisms of stromal and exosome support a future 
work plan will include a study of these interactions using a 3D cell culture model which 
will give us a simplified model of the bone marrow niche allowing us to assess the 
interactions between cell types within an ex vivo setting, providing an important 
element of vasculature and providing a closer study of defined cell interactions and 
produce functional readouts of  cell to cell communication such as movement, 
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adhesion and migration. Experiments could also be carried out under normoxic and 
hypoxic conditions to assess the effect this has on exosome release as this is known 
to be an important factor within the malignant bone marrow microenvironment. This 
model could also be used to differentiate between transient and permanent 
reprogramming taking place due to the ability to switch ‘on and off’ in vitro 
experiments. The fluorescent  labelling of exosomes to track their movement could 
also be incorporated and assessed using confocal microscopy, this was recently used 
in a study investigating the chemoresistant effect created by the AML blast exosome 
instigation of IL8 release from BM stem cells (Chen et al. 2019). To current knowledge 
this methodology has not been used within the context of post-BMT AML and would 
allow closer study of defined cell interactions.  
In summary, AML is a heterogeneous disease which is still fatal for the majority of 
patients within high risk category, it is unlikely that any pharmacological drug 
treatment will resolve the issue of residual disease contributing to relapse therefore it 
is imperative that other strategies are developed to target both pre and post BMT and 
improve treatment. Within this thesis I have successfully isolated and characterised 
extracellular vesicles from normal and pre and post BMT AML patients and shown 
that within a diseased or recovering BM-ME EVs are present in higher levels 
compared to healthy individuals indicating their involvement in promoting malignancy. 
Identification of EV content showed a clear predisposition for immunomodulation 
function post- transplant and an associated miRNA and mIR expression within this 
patient sub-set signified the heterogeneous nature and potential indicative impact it 
could have on therapeutic options. These observations warrant further exploration as 
they could improve understanding of the mechanisms involved in BM remodelling 
within the leukaemic niche and potentially provide an early indicator of relapse. 
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